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Tuberculosis (TB) is an infectious disease caused by a group of species of the 
genus Mycobacterium called the M. tuberculosis complex (1). Transmission of 
TB occurs from a person with active infectious pulmonary TB by airborne 
droplet nuclei derived from droplets of mucus produced by coughing, sneezing, 
or talking, which are subsequently inhaled by other people (2). The resulting 
disease most commonly affects lungs and is called pulmonary TB with symp-
toms of chronic cough, loss of weight, loss of appetite, and general malaise (3). 
According to the World Health Organization (WHO), in 2017, 10 million indi-
viduals became ill with TB and 1.3 million died (4). Approximately 95% of TB 
cases occur in developing countries and nearly one in nine new TB cases occur 
in individuals, who are infected with human immunodeficiency virus (HIV) (4). 
TB is the 10th leading cause of death worldwide and since 2011, it has been the 
leading cause of death from a single infectious agent, ranking above HIV/ Ac-
quired Immunodeficiency Syndrome (AIDS) (4). This is despite the fact that 
with timely diagnosis and correct treatment, most people, who develop TB 
disease, can be cured (5, 6).  
Drug-resistant TB (DR-TB), which is a consequence of failed treatment or 
direct transmission from an individual infectious with DR-TB, threatens global 
TB care and remains a major public health concern in many countries (4). 
Multidrug-resistant TB (MDR-TB), defined as laboratory-confirmed resistance 
to the two most potent first-line medications, isoniazid (INH) and rifampicin 
(RIF), has emerged in widespread proportions in the world's poorest populations 
and risk groups, including prisoners (7). In 2017, there were 558,000 new cases 
with rifampicin-resistance (RR), of which 82% had MDR-TB (4). Globally, in 
2017, an estimated 3.5% of the new cases and 18% of previously treated cases 
had MDR-TB and RR-TB, with the highest proportions (>50% in previously 
treated cases) occurring in the countries of the former Soviet Union (4). Among 
cases of MDR-TB in 2017, 8.5% were estimated to have extensively drug-resis-
tant TB (XDR-TB), defined as MDR-TB with additional resistance to at least 
one fluoroquinolone (FQ) and one injectable agent [amikacin (AM), kanamycin 
(KM), or capreomycin (CM)] (4). Occurrence of XDR-TB was first reported in 
2006 and by the end of the year 2017, it had been reported by 127 countries (4, 
8). 
Approximately 36% of the estimated TB cases and 71% of the estimated 
MDR/RR-TB cases remained undiagnosed in 2017 (4). This gap is mainly due 
to a combination of under-reporting and under-diagnosis, specifically among 
the people, who have poor access to health care, including persons in the correc-
tional facilities. More than 10 million people are held in prisons worldwide, 
with the prevalence of TB among people in the prison setting being 1.528.1 
times of the prevalence among the respective general population (9, 10). 
Furthermore, in the correctional facilities of certain low- and middle-income 
countries, the prevalence of TB is described as up to 64-fold of that found in the 
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general population (11–13). The increased risk of TB in prisons is related to 
high likelihood of particular risk factors among the detainees, such as prolonged 
stay at overcrowded facilities with poor ventilation, TB and HIV co-infection, 
malnutrition, diabetes, smoking, and a history of alcohol and illicit drug con-
sumption, as well as prior TB disease (14, 15). High rates of DR-TB are com-
monly seen in correctional facilities worldwide, but especially, in the countries 
of the former Soviet Union (16). One of the critical barriers to TB control in 
prisons is limited access to the high-quality and early diagnosis of TB, 
inaccuracy of the diagnosis, and the lack of proper laboratory facilities (16, 17). 
Delayed diagnosis and treatment may further increase the risk of TB trans-
mission and poor outcomes (18). To decrease the burden of TB in the peniten-
tiary systems (PSs), WHO has recommended systematic performance of mass 
screening, i.e. systematic screening for active TB in the whole prison popula-
tion, passive case finding, which means detecting TB among symptomatic indi-
viduals, who seek for health care in prisons, and screening for active TB on 
entry to the prison (19, 20). The programs are advised to use rapid diagnostic 
tests for TB, like Xpert MTB/RIF and liquid culture (21). Although the peniten-
tiary facilities could be ideal settings for TB control-related interventions with 
regard to low default rate, the WHO target for successful treatment of MDR-TB 
of at least 75% is rarely reported in prison settings (22). Moreover, the pub-
lished factors associated with either unfavorable or favorable outcomes (incl. 
cure) are often, if not always, confused by the factors associated with loss to 
follow-up. 
After decades of relative neglect, global efforts to control TB were reinvi-
gorated in 1991, when a World Health Assembly resolution recognized TB as a 
major global health problem (23). Since then, several TB control strategies 
including directly observed therapy, short course (DOTS) strategy, the Global 
Plan to Stop TB 2006–2015, and the currently used End TB Strategy were suc-
cessively endorsed (24–26). The goal of the End TB Strategy is 90% reduction 
in TB deaths and 80% reduction in TB incidence rate by 2030 that may lead to 
an annual decline in the incidence of 15% and finally reduce the incidence of 
TB to <1 case per million by 2050 (24, 25). Achievement of this goal, among 
others, will require improvements in TB detection, early diagnosis, and effec-
tive treatment among high risk-groups, including prisoners. 
This current study was performed in the PS of Azerbaijan, the country, 
which is among the 30 high RR-TB-burden countries in the world and among 
the 18 high-priority countries to fight TB in the WHO European Region (4, 10). 
Prior to this study, the reported notification rate of TB in the prisons of Azer-
baijan was 61 times of that among the civilian population, whereas in 2016, the 
TB notification rate in prisons is 18 times of that among the civilian population 
(10, 11). 
The general aim of the study was to evaluate the impact of the WHO-
recommended screening, diagnostics, and treatment to the burden of TB and 
M/XDR-TB in the high-burden, but low-default prison settings. 
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2. REVIEW OF THE LITERATURE 
2.1. Origin and definition of tuberculosis 
TB, an infectious disease caused by a group of Mycobacterium species united 
under the name of M. tuberculosis complex (1). M. tuberculosis is an ancient 
human pathogen, which has plagued countless human societies despite the 
introduction of curative and preventive therapy during the last century (27, 28). 
The human host serves as the natural reservoir for M. tuberculosis (29). Inhala-
tion of aerosol or droplets containing M. tuberculosis with subsequent deposi-
tion in the lungs leads to one of four possible outcomes: immediate clearance of 
the pathogen, immediate onset of active disease called primary TB, latent TB 
infection (LTBI), and onset of active disease many years following a period of 
latent infection, called reactivation disease (29). Following the initial infection, 
the bacteria most often lie dormant without evidence of clinically manifested 
symptoms (30). This state of persistent immune response to previously-acquired 
M. tuberculosis antigens is called LTBI (31). The ability of the host organism to 
efficiently establish latent infection has enabled it to spread to nearly one-third 
of all individuals worldwide (29). Reactivation TB results from proliferation of 
a previously latent bacteria seeded at the time of the primary infection (32). 
Among individuals with LTBI and without an underlying medical problems, it 
has generally been estimated that the lifetime risk of reactivation disease after 
an infection is 5%–10%, with a 5% risk within the two to five years following 
infection and another 5% risk over the remaining lifetime (33). Immunosuppres-
sion is clearly associated with reactivation TB, though it is not clear what 
triggers the latent infection to break containment and become active (30, 34). 
Immunosuppressive conditions associated with the reactivation TB include: 
HIV infection and AIDS, chronic and end-stage renal disease, diabetes mellitus, 
malignant lymphoma, corticosteroid use, anti-tumor necrosis factor-α medica-
tions, diminution in cell-mediated immunity associated with age, and cigarette 
smoking (35–37). The resulting disease most commonly affects the lungs and is 
termed as pulmonary TB with symptoms like chronic cough, loss of weight, 
loss of appetite, and general malaise (3). Extra-pulmonary TB, defined as TB 
not affecting the lungs or larynx, may occur, but it is usually rare and is largely 
not deemed contagious (38). Transmission of TB arises from persons with 
active infectious pulmonary TB by airborne droplets produced by coughing, 
sneezing, or talking and subsequent inhalation by others (2). 
 
 
2.2. Tuberculosis and drug-resistant tuberculosis globally 
More than 2 billion people that account for ~30% of the world’s population are 
estimated to be infected with M. tuberculosis (39). The global incidence of TB 
peaked around 2003 and appeared to be declining slowly after that (4). 
According to the WHO, in 2017, 10 million individuals became ill with TB and 
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1.3 million died (4). The epidemiology of TB varies substantially around the 
world with the highest rates (100 per 100,000 or higher) being observed in Sub-
Saharan Africa, India, and the islands of Southeast Asia and Micronesia. Inter-
mediate rates of TB (26 to 100 cases per 100,000) occur in China, Central and 
South America, Eastern Europe, and northern Africa. Low rates (less than 25 
cases per 100,000 inhabitants) occur in the United States, Western Europe, 
Canada, Japan, and Australia. Poverty, HIV, and drug resistance are major con-
tributors to the resurging global TB epidemic (40). Approximately 95% of TB 
cases occur in the developing countries. Approximately one out of nine TB 
cases occur in individuals, who are infected with HIV and 74% of such cases 
occur in Africa (4). TB is the 10th leading cause of death worldwide and the 
most common infectious cause of death in adults worldwide, ranking above 
HIV/AIDS (4). The majority of TB-related deaths are reported in low- and 
middle-income countries (41–44). This happens despite the fact that with timely 
diagnosis and correct treatment, TB could be a curable disease in most cases (5, 
6). 
DR-TB threatens global TB care and prevention and remains a major public 
health concern in many countries. MDR-TB, defined as laboratory-confirmed 
resistance to the two most potent first-line medications, INH and RIF, has 
emerged in epidemic proportions in the wake of widespread HIV infection 
among the poorest populations and risk groups including prisoners (29). In 
2017, there were 558,000 new cases with RR, defined by resistance to RIF 
detected using phenotypic or genotypic methods, with or without resistance to 
other anti-TB medicines (ATM), of which 82% had MDR-TB (4, 38). Globally, 
in 2017, an estimated 3.5% of the new cases and 18% of the previously treated 
cases had MDR/RR-TB, with the highest proportions (>50% in previously 
treated cases) in the countries of the former Soviet Union (4). Among the cases 
of MDR-TB in 2017, 8.5% were detected to have XDR-TB, defined as MDR-
TB with additional resistance to at least one FQ and one injectable agent (AM, 
KM, or CM) (4).  
 
 
2.3. Strategies for tuberculosis control 
The five-element DOTS strategy was developed by the WHO in the mid-1990s 
as a response to the recognition of TB as a major global health problem. Five 
components were included into this strategy (45): 1) government commitment 
to the TB control, 2) case detection among symptomatic patients, 3) standar-
dized chemotherapy for all sputum smear-positive cases under proper case 
management conditions, 4) regular drug supply, and 5) monitoring system for 
program supervision and evaluation. Several challenges emerged during the 
implementation of DOTS that were not fully addressed in the original World 
Health Assembly recommendations (23). To address these problems, a new plan 
entitled “Stop TB Partnership: The Global Plan to Stop TB 2006–2015” was 
developed by the WHO for 2006–2015 (25, 46). In addition to enhancing the 
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original elements of DOTS, the following additional control components were 
included to reduce the global TB burden: 1) collaborative activities imple-
mented jointly by TB and HIV/AIDS programs, 2) new treatment strategies to 
manage MDR-TB, 3) new community approaches to engage all relevant 
partners in national TB program implementation for expansion of equitable 
access to the diagnosis and treatment, 4) strengthening of the health system to 
address impediments to implementation of the national TB program, 5) es-
tablishment of mechanisms to improve global access to affordable and quality-
assured first- and second-line ATM (47, 48), and 6) intensified research to 
develop better tools for the diagnosis, prevention, and treatment of TB. 
Despite considerable efforts, TB remains a substantial source of global 
morbidity and mortality, mainly due to persisting barriers to the universal health 
coverage (3). Therefore, the End TB Strategy, the current WHO TB strategy, 
has been revised to focus on the most vulnerable individuals, who are infected 
by TB, including prisoners (49). The strategy considers three pillars to address 
the existing barriers to TB care: 1) integrated people-centered TB care and pre-
vention, 2) bold policies and supportive systems, and 3) intensified research and 
innovation (24). The goal of the End TB Strategy is 90% reduction in TB deaths 
and 80% reduction in TB incidence rate by 2030 that may lead to annual 
incidence decline of 15% and finally reduce the incidence of TB to <1 case per 
million by the year 2050. 
 
 
2.4. Tuberculosis in prisons 
More than 10 million people are kept in the prisons worldwide, with the pre-
valence of TB among the imprisoned people being 1.528.1 times of the pre-
valence in the respective general populations (9–13). According to the latest 
data from the European Region, the proportion of new and relapsed TB cases in 
prisons represented up to 10,4% out of the country total TB incidence (10). 
Moreover, in correctional facilities worldwide, higher rates of DR-TB than in 
the general population are commonly seen (10, 50). This has been especially 
clearly shown in the countries of the former Soviet Union, where up to every 
third new TB patient and two thirds of the repeatedly treated TB patients 
reported in the correctional facilities suffered from disease caused by RIF-
resistant M. tuberculosis (10, 11, 51). Given the housing of the prisoners is ge-
nerally overcrowded in the detention settings, each single TB patient, including 
that with DR-TB, may annually infect 10–15 or more other people (52, 53). 
The majority of the people, who are imprisoned globally, are those, who are 
extremely poor, have lacked access to their opportunities throughout the course 
of their lives, and are the most marginalized, which all increase the likelihood of 
having TB (54). The amplified risk of TB, a possibly deadly disease in prisons, 
is related to a high likelihood of plentiful risk factors among the prisoners, such 
as prolonged stay at the overcrowded facilities with poor ventilation, HIV, 
malnutrition, diabetes, smoking, and a history of alcohol and illicit drug con-
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sumption, as well as former TB disease (14, 15). At the same time, by com-
paring DNA fingerprints of the M. tuberculosis isolates from the first and 
second episodes in TB patients with recurrent disease, investigators have shown 
that 77% of the recurrences were new infections rather than relapses (55). In 
prisons, the rate of reinfection TB was four times of the rate of new TB leading 
to a conclusion that the increased risk of active disease in those with prior TB 
may be a reflection of the high prevalence of the disease in the prison settings 
and therefore, high transmission frequency in a community with a large number 
of high-risk hosts (55). This finding is also supported by the results of a mole-
cular epidemiology study carried out in a Brazilian prison showing that high 
prevalence of active TB disease in the correction facility is predominantly 
fueled by intra-institutional transmission (56, 57). Due to the punitive and 
retribution policies still prevalent in many settings, incarceration rates are high 
and prisons are extremely overcrowded, thus providing opportunity for close 
contacts with infectious individuals in circumstances of poor hygiene, inade-
quate ventilation, and concentration of population with high risk for active TB 
(9, 10, 14, 58–64). Consequently, prisoners have virtually no possibility to pro-
tect themselves from airborne contamination, as they “cannot stop breathing” 
(65–68). This is a significant difference, when compared TB with the prevention 
measures available for any contact- or blood-borne diseases transmitted in 
prison, whereby by promoting positive health behavior, the prisoners can 
protect themselves from such diseases (69, 70). 
While the treatment success rates among TB and MDR-TB patients globally 
are below the outlined targets of 85% and 75%, respectively, the respective 
rates among prisoners are even lower (4, 68). Delayed diagnostics of TB, poor 
access to healthcare and effective treatment as well as low adherence are among 
the common reasons for low TB treatment success rates among prisoners. 
Contracting TB in prison is a disaster for the patient and his/her family. At the 
same time, TB in prisons does not stay confined and there is evidence that mass 
incarceration and increased TB prevalence in the countries of Eastern Europe 
and Central Asia has been associated with an increase in TB prevalence in the 
general population (60). It is estimated that 6.3% of the TB in the general 
population in low- and middle-income settings is attributable to the exposure in 
prisons (71). Transmission of TB, however, occurs not only in prisons, but also 
through the contacts with family members, the staff, and upon release, when TB 
is not properly diagnosed or treated or when linkages to the treatment in the 
community are not adequately supported (72). In parallel, there is growing 
evidence to show that the staff in the prisons is at high risk of infection, if TB 
among prisoners is not adequately addressed. A report from Malaysian prisons 
found an 81% prevalence of LTBI among prison staff, which was higher than 
LTBI prevalence among the health care staff (52%) and in the general popu-
lation (32%) of the same state (73). 
Reduction of the TB burden in prisons requires a comprehensive package of 
measures (74): 1) early diagnosis using systematic screening and rapid diag-
nostics, 2) proper infection control, 3) supervised and complete TB treatment 
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with effective drugs, and 4) continuity of care in the public sector, when a 
prisoner under treatment is released. Many of the listed factors have been 
investigated in relation to addressing the TB burden in the general population 
(75–79). However, in the prison settings with high burden of TB and RR-TB, 
the efficiency of measures to decrease the burden of TB and the determinants of 
the outcome of the treatment of RR-TB have not been explicitly addressed 
before. Theoretically, the prison setting implies having prisoners all in one place 
and hence, offers a great opportunity for TB control, if also coupled with ade-
quate linkage to the care after release (80). However, despite being a serious 
cause of morbidity and mortality among the incarcerated populations, in gene-
ral, many prison systems with high TB burden lack proper TB control, in-
cluding lack of professional human resources, laboratory capacity, diagnostic 
tools, treatment options, and financial investments (16, 81). This results in poor 
treatment outcomes, often related to treatment interruption and weak integration 
of prison TB services with the civilian ones (16). Therefore, there is also a lack 
of evidence and results from research on effective measures to control TB in the 
high RR-TB-burden penitentiaries. Moreover, health care in the correctional 
facilities in most of the prison systems with high TB burden is governed by the 
ministries other than the Ministry of Health (e.g. the Ministry of Justice, 
Ministry of the Interior etc.), which often pose additional barriers and limits 
access to the prison- and prisoner-related data (82). 
 
 
2.5. Tuberculosis case finding 
Around 36% of the estimated incidence or about 4 million TB cases in the 
general population worldwide remained undiagnosed in 2017 (4). Detection and 
treatment of MDR-TB are also inadequate. The WHO estimates that only 29% 
of patients with MDR-TB were identified and put on the second-line treatment 
in 2017 (4). 
Systematic screening for active TB, i.e. the systematic identification of 
people with suspected active TB in a predetermined target group, using tests, 
examinations, or other procedures that can be applied rapidly, is one of the key 
measures for the prevention and control of TB (19). The role of systematic 
screening for active TB is of utmost importance in prisons due to high TB 
burden and risk factors among prison population, as well as decent environment 
for transmission of M. tuberculosis. To improve the epidemiological situation in 
PS, WHO recommends performance of mass screening, i.e. systematic 
screening for active TB for the whole prison population, passive case finding, 
i.e. detecting TB among symptomatic individuals, who seek for healthcare in 
prisons, and screening for active TB on entry to the correctional facility (19, 
20). It supports early diagnosis, ensures people with active disease with early 
treatment and care, and thus contributes to prevent onward the disease trans-
mission (3, 19). Body mass index (BMI) ≥18.5 kg/m2 and minimal changes at 
the chest radiography at the time of the TB diagnosis may serve as a good proxy 
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for early diagnosis, since as a result of intoxication, TB may just be the cause of 
low BMI and the earlier pulmonary TB is detected, the smaller are TB lesions 
on the chest radiography (19, 77, 83–85). At the same time, the TB programs 
are advised to include rapid diagnostic tests for TB like Xpert MTB/RIF and 
liquid culture for detection of TB. However, at present, there is limited evidence 
to demonstrate that inclusion of the rapid diagnostic tests into mass screening or 
passive case finding algorithms along with the related financial load is justified 
to significantly reduce the burden of TB in prisons. As a result, major hetero-
geneity in TB case finding approaches has emerged in the prisons worldwide 
(16, 86). According to the latest review, two thirds of low- and middle-income 
countries use symptom questionnaires and one third uses chest radiography for 
systematic screening in prisons, coupled with sputum acid-fast bacilli (AFB) 
smear and solid culture as a diagnostic tool (86). By now, the impact of rapid 
diagnostic tests in high-TB/RR-TB-burden prisons have been demonstrated 
only by modeling TB epidemiology or by limited application among HIV-
infected prisoners (17, 87). To the best of our knowledge, there are no studies 
providing evidence on the impact of systematic screening enhanced with rapid 
diagnostic tests to the TB epidemiology in high-TB/RR-TB-burden prison 
settings. At the same time, this kind of information is necessary to guide future 
decisions directed to improvement of TB control in prisons. 
 
 
2.6. Diagnosis of tuberculosis 
Tuberculin skin test (TST) developed about a century ago continues to be the 
main test for diagnostics of LTBI in low- and middle-income countries (88). 
This involves the intradermal injection of purified protein derivative, which 
leads to a delayed-type hypersensitivity response causing a cutaneous induration 
at the site of injection which peaks at 48–72 hours (89). A positive TST indi-
cates previous exposure to M. tuberculosis or other non-tuberculous myco-
bacteria or prior bacillus Calmette–Guerin (BCG) vaccination (90–93). At the 
same time, the specificity of TST is compromised by repeated BCG vaccina-
tions and/or exposure to non-tuberculous mycobacteria and has limited predic-
tive value for TB disease (94, 95). The sensitivity of the test may be also low in 
individuals with suppressed immunity (91, 96). The use of TST in high-TB-
burden prisons of low- and middle-income countries is limited by ongoing or 
recently stopped BCG revaccination policy, the deficit of trained personnel, and 
the focus on TB disease control, due to the high burden. 
Another test for detect M. tuberculosis exposure is interferon-γ assay 
(IGRA), which is based on the principle that T cells of individuals, sensitized 
with the antigens of M. tuberculosis, produce interferon-γ, when they re-
encounter mycobacterial antigens (88). Although the results of IGRA are not 
affected by BCG vaccination, still they have not overcome the problem of the 
limited positive predictive value of TB disease (97). At the same time, the wide 
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use of IGRA in low- and middle-income countries, including in prison settings, 
is restricted due to the high cost of this test. 
The presence of pulmonary TB disease should be suspected in patients with 
relevant clinical manifestations including cough for more than 2-week duration, 
fever, night sweats, and weight loss. The diagnosis of pulmonary TB is definiti-
vely established by isolation of M. tuberculosis from a body secretion, such as 
sputum, bronchoalveolar lavage fluid, pleural fluid, or tissue obtained through 
pleural or lung biopsy (98). Additional diagnostic tools include sputum AFB 
smear and nucleic acid amplification (NAA) testing. (99) In patients with a 
suspicion of TB, two sputum specimens, obtained via cough or sputum induc-
tion at least eight hours apart and including at least one early-morning speci-
men, should be submitted for AFB smear, mycobacterial culture, and NAA 
testing (98, 99). 
Sputum smear microscopy is a technique developed for more than 100 years 
ago. It requires examination of samples under a microscope to determine the 
presence of bacteria. Two types of staining are most commonly used for the 
detection of mycobacteria: carbol-fuchsin staining (Ziehl-Neelsen, Kinyoun) 
and fluorochrome staining (auramine, auramine-rhodamine) (99). Currently, 
sputum smear microscopy is rarely used for the purposes of diagnosis, rather is 
the sputum smear status used to monitor the response to treatment, to guide the 
infection control practices, and to direct contact investigations (99, 100). 
Conventional culture is the most sensitive tool for detection of TB and can 
detect as few as 10 bacteria in milliliter of sample. There are three types of tra-
ditional culture media: solid egg-based [Löwenstein-Jensen (LJ)], solid agar-
based (Middlebrook 7H10 or 7H11), and liquid media, such as Middlebrook 
7H12 and 7H9. The latter is used as a medium for the mycobacterial growth 
indicator tube (MGIT) automated M. tuberculosis culture system (Becton Dic-
kinson Diagnostic Systems, Sparks, MD, USA). WHO recommends liquid 
media for the diagnostics of TB, since growth in this media is faster (in general, 
1–3 weeks) than growth on solid media (3–8 weeks) (99, 101). Once growth is 
detected, a sample out of it should be processed or forwarded for the identifica-
tion of the species and drug susceptibility testing (DST) to ATM. DST may be 
conventional (phenotypic) culture-based or molecular (genotypic) NAA test 
(99). 
Culture-based DST allows comparison of growth on drug-containing me-
dium with growth on control medium to establish the presence or absence of 
drug-resistance. The breakpoint between a resistant and a susceptible strain is 
established via the “critical concentration”, which is the level of the drug in the 
culture medium that inhibits 95% of wild-type TB strains, but does not appre-
ciably suppress the growth of strains that are resistant to the drug. Currently, the 
critical concentrations are available to almost all ATM, including bedaquiline 
(BDQ) and delamanid (DLM) (102).  
Molecular NAA tests for DR-TB have faster turnaround time than the 
culture-based DST (results are available within hours to days) and are useful for 
guiding initial decisions regarding therapy until the definitive culture-based 
19 
DST results are available. Xpert MTB/RIF and Line Probe Assays (LPA) 
techniques are currently recommended by WHO for the molecular diagnosis of 
TB and DR-TB (103). The Xpert MTB/RIF assay is a molecular beacon assay 
for simultaneous detection of M. tuberculosis and RIF-resistance mutations in 
an 81-bp region (codons 426 to 452) of the rpoB gene, known as the RIF-
resistance–determining region (104, 105). The assay is a fully integrated, closed 
system designed for testing clinical specimens in low-level laboratories and 
primary health care clinics and may be used for sputum smear-positive or 
smear-negative samples from adults with suspected pulmonary TB. The test has 
dramatically reduced the time to RR-TB diagnosis and the time to initiation of 
effective therapy, since the results can be available within two hours (106–108). 
The Xpert MTB/RIF assay has up to 98% sensitivity and up to 99% specificity 
in the detection of M. tuberculosis, as well as up to 98% sensitivity and 98% 
specificity in detection of resistance to RIF (102, 104). The Xpert MTB/RIF 
assay received endorsement by the WHO in 2011 and approval by the Federal 
Drug Agency in 2013 (109, 110). In 2017, the WHO recommended use of Xpert 
MTB/RIF Ultra as a replacement for Xpert MTB/RIF in all settings, due to its 
higher sensitivity for the detection of M. tuberculosis in specimens with low 
number of bacilli and at least as good accuracy for the detection of RIF-
resistance (111). Since early detection of RIF-resistance with prompt treatment 
are the cornerstones of effective TB control, WHO, along with the conventional 
culture-based DST, recommends performance of Xpert MTB/RIF for rapid 
detection of TB and RR-TB (102, 110, 112). However, sometimes may Xpert 
MTB/RIF and phenotypic tests show opposing RIF-susceptibility results or so-
called discordant results (113). Among the reasons behind the discordant RIF-
susceptibility results, one is that a range of commercial systems for RIF-resis-
tance detection, including Xpert MTB/RIF, targets the 81-bp core region of the 
rpoB gene shown to be associated with 95–98% of the resistance to RIF in M. 
tuberculosis (38, 114–117). Consequently, such systems are prone to miss RIF-
resistance associated with the remaining genome, which would be still detected 
by the phenotypic tests. Other mechanisms of RIF-resistance, such as decreased 
cell wall penetrability to drugs and active efflux pumping, are also considered to 
be important in conferring resistance in the isolates without detectable target 
gene mutations (118, 119). Nevertheless, recent findings indicate that although 
the efflux pumps play an important role in the acquired resistance to INH, they 
contribute significantly less in determining the RIF-resistance (120). Some 
studies also mention occurrence of silent mutations responsible for false-
positive RIF-resistance results by Xpert MTB/RIF (121, 122). Mutations of the 
rpoB gene conferring low-level resistance are associated with a delay in growth 
on MGIT phenotypic testing, which may also lead to discordant RIF-suscepti-
bility results (123). The discrepancy among the RIF-susceptibility results by 
molecular and phenotypic tests may additionally be influenced by heterogeneity 
of the examined sputum samples and detection of genetically different strains 
that might oroginate from separate lesions in the lungs, which contain different 
M. tuberculosis strains and open simultaneously or consecutively (124–128). 
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Furthermore, increasing the number of collected and analyzed sputum samples 
might also increase the likelihood of detection of genetically different strains 
(129). To decrease such divergences, TB programs use the same sputum sample 
simultaneously for both phenotypic and genotypic examination, which is chal-
lenging, scientifically unproven, and costly, considering that two samples are 
obtained for the diagnostic purposes. 
The LPA techniques recommended by WHO include: MTBDRplus for 
detecting mutations that determine resistance to RIF and INH (rpoB gene for 
RIF-resistance; katG and inhA genes for INH resistance) and MTBDRsl for 
detecting resistance to FQ and injectable agents (second-line ATM; gyrA gene 
for FQ resistance and rrs gene for injectable agents) (99, 130). LPA techniques 
are widely applied on cultured material, but have also been approved for direct 
use in clinical specimens, although with reduced sensitivity in smear-negative 
samples (131). Compared to Xpert MTB/RIF, LPA techniques are methodo-
logically more complex requiring separate workstations for DNA extraction, 
polymerase chain reaction, and hybridization, as well as are prone to contamina-
tion similarly to other molecular assays that use open systems (132, 133). 
Urine antigen test is a urine-based detection of mycobacterial cell wall 
glycolipid lipoarabinomannan in urine, which is a point-of-care assay for the 
diagnosis of TB recommended by WHO for regions of the world with high 
incidence of HIV and TB co-infection (134). This test is recommended in 
addition to routine diagnostic tests for HIV-infected patients with signs and 
symptoms of pulmonary and/or extrapulmonary TB and CD4 ≤100 cells/µL and 
for HIV-infected patients, who are seriously ill (defined as respiratory rate 
>30/minute, body temperature 39°C, heart rate >120/minute, and unable to walk 
unaided), regardless of the peripheral CD4 cell count (134). 
TB-LAMP is a manual molecular method for detection of TB, based on the 
loop-mediated isothermal amplification platform (LAMP) (135). According to 
WHO, TB-LAMP may be used as a replacement test for sputum-smear micro-
scopy to diagnose pulmonary TB or as a follow-on test to smear microscopy in 
adults with signs and symptoms consistent with pulmonary TB (136). 
WHO also recommends the selective use of one or more of the following 
non-commercial culture and DST methods for rapid screening of patients 
suspected of having MDR-TB in reference laboratories and under strict labo-
ratory protocols: nitrate reductase assay (NRA), the colorimetric redox indicator 
(CRI) method, and microscopic observation drug susceptibility (MODS) assay 
(137). NRA is a colorimetric method of DST, based on the ability of M. tuber-
culosis to reduce nitrate, which is detected by a colored reaction (138, 139). 
According to a recent systematic review, the sensitivities of NRA for INH and 
RIF resistance are 95.4% and 96.4%, respectively and the specificities are 
98.5% and 99.2%, respectively (138). MODS assay is a direct microcolony 
method in liquid culture, based on inoculation of specimens to drug-free and 
drug-containing media, followed by microscopic examination of the early 
growth (140, 141). For the MODS assay of RIF and INH resistance, the sensi-
tivities are 98.0% and 97.7%, respectively and the specificities are 99.4% and 
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95.8%, respectively (142). CRI is an indirect testing method, based on the 
reduction of a colored indicator added to liquid culture medium in a microtiter 
plate after in vitro exposure of M. tuberculosis strains to ATM (143). Sensiti-
vities of the CRI test for RIF and INH resistance are reported to be 99% and 
98%, respectively, whereas the specificities are 99.8% and 99%, respectively 
(143, 144).  
 
 
2.7. Treatment of tuberculosis 
Without treatment, the mortality rate from TB is high. Studies of the natural 
history of TB disease in the absence of treatment with ATM, conducted before 
drug treatments became available, found that about 70% of individuals with 
sputum smear-positive pulmonary TB died within 10 years of being diagnosed, 
as did about 20% of people with culture-positive (but smear-negative) pulmo-
nary TB (145). The currently used ATM are classified as first- and second-line 
drugs with the latter used to treat disease that is resistant to first-line therapy. 
Compared with the first-line drugs (FLD), the second-line drugs (SLD) are less 
effective, more toxic, and/or have not been studied as extensively. It should be 
mentioned that the activity of the ATM differs from bactericidal to sterilizing 
and bacteriostatic (146). The recommended treatment for cases of drug-
susceptible TB is a 6-month regimen of four first-line drugs: INH, RIF, etham-
butol (EMB), and pyrazinamide (Z), all of which, but Z, have bactericidal 
activity, i.e. the capacity to kill M. tuberculosis (147). The latest data on the out-
comes of FLD treatment show a global treatment success rate of 82% (4). 
Compared to drug-susceptible TB, RR-TB is difficult and costly to treat with 
the treatment results usually being with a markedly lower success (148). Until 
early 2016, the treatment regimens recommended by WHO typically lasted for 
20 months and included Z and at least four core SLDs of which two were 
bactericidal (FQ and injectable ATM) and two were companion bacteriostatic 
drugs [cycloserine (CS)/terizidone (TZD), para-aminosalicylic acid (PAS), or 
ethionamide (ETO)/prothionamide (PTO)] (102, 149). The latest data show that 
effectiveness of this treatment is not optimal with success rates reaching 
globally only 55% (4). Moreover, a meta-analysis revealed almost the same 
treatment success rate (148). The 2016 WHO guidelines proposed using so-
called ABCD classification to build a regimen for drug-resistant TB taking into 
account contra-indications, such as DST results showing resistance, history of 
adverse drug events, and previous drugs used in the regimen that was a failure 
(150, 151). For RR-TB, four core ATM should be chosen one from the group A 
(FQ), one from the group B (second-line injectables), and at least two from the 
group C [ETO/PTO, CS/TZD, linezolid (LZD), and clofazimine (CFZ)] (150). 
At the same time, if the minimum of effective ATM cannot be composed, an 
agent from the group D2 BDQ, DLM, or imipenem-cilastatin) could be added to 
bring the total number of drugs to five (150). As a result, in case of resistance or 
intolerability to both group A and group B ATM, regimens built totally on the 
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drugs from the group C would be an acceptable option (151). The fluoroquino-
lones, the second-line injectables, LZD, BDQ, and DLM are SLD with high 
bactericidal activity (151). Hence, the regimen built only of the group C drugs 
could be weak with only one ATM possessing high bactericidal activity. Re-
cently, WHO announced the key changes to treatment of MDR/RR-TB through 
regrouping of ATM according to the balance of effectiveness and safety, so-
called ABC classification (152). According to these recommendations, the regi-
mens should be designed sequentially going down the three groups: group A 
(FQ, BDQ, LZD), group B (CFZ, CS/TZD), and group C (AM, EMB, DLM, Z, 
imipenem-cilastatin, ETO/PTO, PAS). As a result, increased number of bacteri-
cidal ATM is warrantied at the start of treatment. Consequently, one of our 
hypothesis was that DST-based individualized treatment with maximal use of 
bactericidal drugs throughout the treatment course is the main factor leading to 
the cure from RR-TB. 
Although the penitentiary facilities would offer perfect settings for TB 
control-related interventions because of the possibility to keep the inmates 
together and more easily under observation, the TB treatment outcomes among 
inmates are inferior compared to the civil population (22, 72). Factors that are 
deemed to be associated with treatment results among inmates are frequently 
affected by factors leading to low treatment adherence. Reliable data on the 
factors associated with cure of RR-TB are scarce. This is particularly the case 
for prisons, where good TB control practice is usually lacking. 
 
 
2.8. Tuberculosis in Azerbaijan and  
in the penitentiary system of Azerbaijan 
Azerbaijan is among the 30 high-RR-TB-burden countries in the world and 
among the 18 high-priority countries to fight TB within the WHO European 
Region (4). In 2007, i.e. the year preceding the current study, in Azerbaijan, 
there were an estimated number of 6,530 incident TB cases (77 per 100,000). 
Of them, 3,916 were MDR/RR-TB cases and the fractions of RR-TB among the 
newly detected and previously treated patients were 22% and 56%, respectively 
(153). According to the recent data, estimated 6,500 incident TB cases (67 per 
100,000 population) and 2,100 MDR/RR-TB cases (22 per 100,000 population) 
emerged in the country in 2017 (4). Based on the national drug-resistance 
survey from 2013, the fraction of RR-TB in the country was 13% and 28% 
among the new and previously treated patients, respectively (154). The detec-
tion of XDR-TB cases remains at 18–19% out of the MDR-TB cases for the 
recent years (4). 
The average annual number of detainees in the PS of Azerbaijan is about 
20,000. In 1994, the prevalence of TB in Azerbaijan prisons was reported as 
almost 50 times higher than the country’s average with the mortality being as 
high as 24% (59). Moreover, 10% and 34% of the new and repeatedly treated 
TB cases in Azerbaijan prisons, respectively, had RR-TB (11). According to 
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Aerts et al. in 2002, the prisoners-to-civilians TB notification ratio was as high 
as 61 (11). In 2016, the incidence of TB in the Azerbaijan PS was 1,217 per 
100,000 prisoners, which was still 18 times of the rate among the civilian 
population (10). 
In 1995, Azerbaijan introduced the WHO DOTS strategy to enable TB care 
and control in the prisons of the country. Since then, all WHO-recommended 
TB control interventions including systematic screening, diagnostics, and treat-
ment were diligently implemented in the Azerbaijan correctional facilities and 
acknowledged by the international TB society (25, 155, 156). Systematic 
screening for TB cases has been performed in Azerbaijan prisons since 2009. 
The program practices early diagnostics using WHO-recommended conven-
tional liquid culture and DST, as well as the molecular diagnostics including 
Xpert MTB/RIF and LPA. Since 2013, the diagnostic algorithm in the Azerbai-
jan PS includes simultaneous examination of sputum samples from all cases 
with presumable TB with Xpert MTB/RIF and MGIT based culture and DST 
for the FLD and SLD (155). All identified cases in prisons of both drug-
susceptible TB and DR-TB are ensured with access to adequate treatment in the 
prison TB hospital – Special Treatment Institution (STI). All patients are 
hospitalized for the full duration of treatment in the STI, where in addition to 
enriched food, they receive additional incentive packages. After the release 
from the prison, the patients continue their treatment in the civilian services, 




2.9. Summary of the literature review 
About 30% of the world population is estimated to be infected with M. tuber-
culosis, more than 10 million individuals become ill and about 2 million die of 
TB annually. Even though TB/RR-TB in prisons remains considerably under-
diagnosed, still the reported morbidity and mortality from this disease among 
incarcerated populations remains times higher compared with the general 
population. Upgrading of TB care, including screening, diagnostic, and treat-
ment in prisons is among the essential perquisites towards ending TB globally 
by 2050. A lack of evidence on impact of rapid diagnostic tests to TB/RR-TB 
burden in prisons contributes to sustained obsolete screening practices among 
inmates. While performance of both the liquid culture-based DST and Xpert 
MTB/RIF is recommended for detection of TB and RR-TB, the programs 
occasionally face with the discordant RIF-susceptibility results. To minimize 
such divergences, laboratories use the same sample for both tests, which is chal-
lenging, scientifically unproven, and costly, considering that two samples are 
obtained for the diagnostic purposes. High rates of cure from RR-TB are rarely 
achieved among general population and even less among prisoners. There is a 
shortage of studies on principal determinants leading to cure from RR-TB, 
which are not biased by low compliance with treatment. 
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3. AIMS OF THE STUDY 
The general aim was to evaluate the impact of the WHO-recommended syste-
matic screening, diagnostics, and treatment to TB and M/XDR-TB burden in the 
high-burden and low-default prison settings. 
 
The specific aims of the studies were: 
 
Study I  To evaluate the impact of systematic mass screening and passive 
case finding to the notification and treatment outcomes of TB in 
high-TB/RR-TB-burden prisons of Azerbaijan before and after 
introduction of the rapid diagnostic tests to the systematic mass 
screening and passive case finding algorithms. 
 
Study II To identify, if the rate of discordant RIF-susceptibility results by 
Xpert MTB/RIF and MGIT is independent on whether the same 
sputum sample or sequential samples are used for molecular and 
phenotypic tests with detection of the rpoB mutations in strains 
with the discordant RIF-susceptibility results and assessment of the 
treatment outcomes among the respective patients. 
 
Study III To clarify, whether the DST-based individualized treatment with 
maximal use of bactericidal drugs throughout the treatment course 
is the main factor leading to cure in RR-TB through assessment of 
the determinants of cure among the RR-TB patients with an em-
phasis on treatment regimen-related issues, taking the advantage of 





4. MATERIALS AND METHODS 
This section encompasses the study population, definitions, study design, labo-
ratory methods, treatment regimens, and modalities of TB and MDR/RR-TB 
management, data collection, and statistical methods. 
 
 
4.1. Study population 
This thesis is based on the results of three studies (I–III), which were carried out 
on partly overlapping cohorts consisting of subjects diagnosed with TB or 
MDR/RR-TB in the PS of Azerbaijan. The partly overlapping cohorts and the 
different time periods of the studies were determined by the specific aims and 
timing of the studies. The study protocol was approved by the Bioethics 
Committee at the Ministry of Health (March 11, 2015, Baku, Azerbaijan). 
The study I included all new and relapse cases of TB notified in all prisons 
of Azerbaijan during the period from January 2009 through December 2015. 
Retreatment TB cases, other than relapses were excluded. Sputum or culture 
samples collected before treatment initiation from new and retreatment TB 
patients diagnosed during January 2010 to January 2015 in the PS of Azerbaijan 
were included in the study II. All new and previously treated patients with 
pulmonary RR-TB undergoing their first treatment episode with the second-line 
ATM in the PS of Azerbaijan during the period from April 2007 to February 




The WHO definitions for drug resistance, patient registration groups, and the 
treatment outcomes were used in studies I–III (38). 
In the study I, systematic screening for active TB was defined as the syste-
matic identification of people with suspected active TB, in a pre-determined 
target group using tests, examinations, or other procedures that can be applied 
rapidly (19). The passive case finding was defined as detection of TB among 
symptomatic individuals, who seek for health care in prisons (19). Mass 
screening signified systematic screening for active TB among the whole prison 
population (20). 
In the study II, strains showing contradictory RIF-susceptibility results, 
when tested by both Xpert MTB/RIF and MGIT-based drug susceptibility tests, 
were termed as strains with discordant RIF-susceptibility results. 
In the analyses of the studies I-III, “cured” and “treatment completed” were 
collectively defined as “favorable treatment outcome”. Death (of any cause) and 
treatment failure were defined collectively as “unfavorable treatment outcome”. 
RR-TB was defined as resistance to RIF according the DST performed on the 
patient’s isolate collected at the start of treatment.  
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In the study III, the patients with MDR-TB, whose isolates were resistant to 
either a FQ or any of the second-line injectables, were defined as having pre-
XDR-TB. In cases, where the M. tuberculosis isolate was tested to be resistant 
against a selected drug in vitro, the particular drug, as well as the drugs with 
known cross-resistance with the latter drug, were considered to be “non-
effective” in vivo (102, 157). Any patient, who was transferred out of the PS 
during treatment and did not have treatment outcome by the time of his/her 
expected treatment completion, was considered as “lost-to-follow-up”. 
 
 
4.3. Study design 
In the context of study I, prior to 2009, systematic screening for active TB was 
not performed in the prisons of Azerbaijan. In January 2009, annual mass 
screening was launched in the correctional facilities to consist of a standardized 
five-symptom TB questionnaire (cough, sputum production, subjective weight 
loss, loss of appetite, and chest pain) and chest radiography (I, Figure 1). 
If any of the five TB symptoms were present or any relevant radiographic 
abnormalities were detected (irrespective of whether the abnormalities were 
considered suggestive of active or inactive TB), a single sputum sample was 
collected and tested by smear microscopy and LJ culture (I). The patients with a 
positive microscopy and/or LJ culture result were isolated and referred to the 
prison TB hospital for further diagnosis and treatment. During the same period, 
identification of presumptive TB cases by passive case finding was performed 
based on the presence of cough for >2 weeks (I). The respective cases were 
isolated and referred to the prison TB hospital for further diagnosis and 
treatment. In the study I, this period lasted from January 2009 to December 
2011 was defined as the pre-intervention period. 
From January 2012, sputum samples from all presumptive TB cases, iden-
tified by having either any of the TB symptoms or any abnormality suggestive 
of TB on chest X-ray during the annual mass screening, were tested by liquid 
culture, based on the MGIT (I). Patients with positive culture result were 
referred to the prison TB hospital for treatment. During the same period, the 
passive TB case finding was carried out through the identification of cases with 
cough for >2 weeks with the following Xpert MTB/RIF testing. The patients 
with positive Xpert MTB/RIF results were also referred to the prison TB 
hospital for treatment. For the study I, this period from January 2012 to Decem-
ber 2015 was termed as the post-intervention period. Additionally, during the 
post-intervention period, the inmates admitted to the non-TB prison hospitals 
were screened using standardized five-symptom questionnaire and chest X-ray. 
In cases, where either any TB symptom was present or any radiographic abnor-
malities were detected, sputum was tested with Xpert MTB/RIF, followed by 






Figure 1. Algorithms of tuberculosis (TB) case finding used in the correctional facilities 
of Azerbaijan during the whole study period (2009–2015) used in the study I. 
LJ=Löwenstein-Jensen, MGIT=Mycobacterium tuberculosis growth indicator tube; 
MTB=Mycobacterium tuberculosis; RIF=Rifampicin; TB=Tuberculosis. Reproduced 
with permission from the publisher (I).  
 
 
In the study II, the first sputum sample from patients diagnosed in Azerbaijan 
PS during 2013–2015 was examined directly with Xpert MTB/RIF, whereas the 
second one was sent for culture and DST on MGIT. Since 2010, in addition, all 
positive cultures processed at the prison system laboratory were frozen and 
archived, including the MGIT cultures. Taking an advantage of this archive, 
Xpert MTB/RIF tests were done retrospectively on additional strains revived 
from the frozen positive MGIT-based cultures performed from samples 
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collected at patients’ diagnosis (II). The obtained results were compared with 
the previously performed MGIT-based DST from the same culture. Whenever 
discrepant results appeared, the tests were repeated by two different technicians. 
The strains that showed discrepant RIF-susceptibility were sent to the Supra-
national Reference Laboratory (SNRL) in Borstel, Germany, for retesting, 
determination of RIF-susceptibility to different concentrations of rifampicin on 
LJ solid medium, and sequencing of the rpoB gene. Patients with discrepant 
RIF-susceptibility results were enrolled to treatment with FLD or SLD, based 
on DST result available at the time of enrollment, TB-treatment history, and 
clinical judgment on the risk of RR-TB (II).  
In the study III, all new and previously treated patients with confirmed 
pulmonary RR-TB undergoing their first treatment episode with SLD in the 
Azerbaijan PS during the period 2007–2013 were included. The treatment 
regimens consisting of at least four effective ATM were individually tailored 
according to the DST results (III). Treatment with SLD was started immediately 
after resistance to RIF was documented by any method. The empirical treatment 
regimens consisting of one second-line injectable, a FQ, Z, and two or three 
drugs from CS, ETO, and PAS were started in cases, where all DST results 
were not available at the start of treatment. The treatment regimen was adjusted 
appropriately after the DST results became available. LZD, CFZ, BDQ, and 
DLM were not available in the PS during the study (III). Drugs were ad-
ministered under direct observation six times weekly throughout the course of 
treatment for at least 18 months with the second-line injectables continued for 4 
months after bacteriological conversion by culture, but not less than a total of 8 
months (III). 
 
4.4. Laboratory tests 
All tests were primarily performed at the STI TB laboratory that performs all 
WHO-recommended laboratory diagnostic tests for TB in line with the good 
clinical laboratory practice standards and with external quality control provided 
by the SNRL in Borstel, Germany, since 2007 (21, 99, 158). 
In the studies I and II, the following tests were performed:  
 The Xpert MTB/RIF test was done using the G4 version of cartridges 
following manufacturer’s instruction (Cepheid, Sunnyvale, CA, USA). 
Starting from March 2013, unprocessed first sputum samples from patients 
admitted to prison TB Hospital for the diagnosis of TB were used for direct 
Xpert MTB/RIF testing. Xpert MTB/RIF testing was also done on strains 
revived from the frozen positive MGIT-based cultures of patients admitted 
to the prison TB Hospital during June 2011–February 2013. 
 The samples were processed by the standard decontamination protocol using 
NALC-NaOH method with the final sodium hydroxide (NaOH) concentra-
tion of 1% (159). Following centrifugation, the supernatant was discarded and 
the pellet was dissolved in 1–1.5 mL of phosphate-buffered saline (PBS). 
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 The sputum samples were inoculated in MGIT for liquid culture and on two 
slopes of LJ solid medium for the quality assurance purposes. Capilia TB-
Neo (Tauns Laboratories Inc., Izunokuni, Japan) or SD-Bioline (Standard 
Diagnostics Inc., Yongin, Korea) rapid tests for detection of AgMPT64 were 
used to identify the M. Tuberculosis isolates. RIF-susceptibility was exa-
mined on MGIT as an indirect test by the proportion method with RIF  
(1.0 μg/mL) (160). The strains showing discordant RIF-susceptibility results 
were repeatedly cultured at the SNRL. RIF-susceptibility was also examined 
on LJ solid medium using 16 µg/mL and 32 µg/mL concentrations of RIF. 
The use of these concentrations was required by the standard operating 
procedures approved and required by the SNRL in Borstel, Germany. 
 The discordant strains repeatedly cultured at SNRL were analyzed by se-
quencing of the rpoB hot spot region. The DNA extract was amplified with 
the primers TR8 and TR9 to amplify the 81-p region within the rpoB gene 
(Thermo Fisher Scientific, Waltham, MA, USA) (161). The primers used for 
PCR were also used for direct sequencing of both strands of the amplifica-
tion products using the automated ABI Prism 377 DNA sequencer and 
corresponding kits (Thermo Fisher Scientific). Spoligotyping was performed 
with use of the standard membrane-based method and the patterns were 
assigned a Spoligo International Type number according to the SITVIT 
WEB International database (161, 162). Direct sequencing of the PCR pro-
ducts was carried out with an ABI Prism 3100 capillary sequencer (Applied 
Biosystems, Carlsbad, CA, USA) and the ABI Prism BigDye Terminator kit 
v.1.1 (Applied Biosystems) according to manufacturer’s instructions. 
 
In the studies I and III, all cultures were done using conventional LJ solid media 
and BACTEC broth media using a fluorometric BACTEC MGIT960 system 
(Becton Dickinson, Sparks, MD, USA). The DST was performed as an indirect 
test by the proportion method RIF (1.0 µg/mL), INH (0.1 µg/mL), streptomycin 
(SM) (1.0 µg/mL), EMB (5.0 µg/mL), Z (100.0 µg/mL), KM (30.0 µg/mL), CM 
(40.0 µg/mL), AM (1.0 µg/mL), PTO (40.0 µg/mL), PAS (1.0 µg/mL), 
ofloxacin (OFX) (0.5 µg/mL), and moxifloxacin (MFX) (0.25 µg/mL) (163). 
The DST to levofloxacin (LFX) and ETO was not done. Since January 2013, 
the rapid tests, Xpert MTB/RIF, and LPA MTBDRplus, were used at the start of 
treatment. If resistance was identified to INH and/or to RIF, the respective 
isolate was tested against the rest of the FLD (SM, EMB, and Z) and SLD (KM, 






4.5. Treatment of tuberculosis in the Azerbaijan 
penitentiary system 
Treatment strategies employed at the Azerbaijan PS were unchanged during the 
whole study period (I–III). All inmates, as soon as they were diagnosed with 
TB, received free standardized treatment with FLD for drug-susceptible TB or 
individualized treatment with SLD for RR-TB in accordance with the WHO 
recommendations available at the time of the study (102). The treatment with 
SLD was prescribed to the patients with available RIF-resistance results at the 
time of diagnosis obtained by MGIT or Xpert MTB/RIF. The SLD regimens 
were individually tailored according to the DST results and contained at least 
four effective ATM given to patients under direct observation on six days per 
week for the whole course duration. The treatment was started immediately 
after the RIF-susceptibility was documented. The empirical SLD treatment 
regimens consisted of one second-line injectable, a FQ, Z, and two or three 
drugs from CS, PTO, and PAS and were started in cases, where the full scale of 
DST results was not yet available at the start of treatment. The empirical treat-
ment was revised as soon as DST results to remaining ATM were ready. New 
ATM, such as BDQ and DLM, as well as LZD and CFZ, were not accessible in 
the PS during the studies. The injectables were continued for four months after 
the bacteriological conversion by culture, but not for less than a total of eight 
months. The overall duration of treatment with SLD lasted for 12 months after 
the culture conversion or for at least 18 months altogether. TB treatment for 
inmates was performed in the prison TB hospital and continuation ensured at 
the civilian sector if the sentence came to an end during the treatment course. 
 
 
4.6. Data collection and analysis 
The data from screening reports, medical charts, and bacteriology laboratory 
reports were entered into the Azerbaijan PS TB registry database (EpiInfo 
6.04d, Atlanta, GA, USA) (164) that served as the source for data transfer into 
the database for the current studies (I-III). The following variables were trans-
ferred and used in the study I: 1) sputum smear microscopy and culture results, 
RIF-resistance, and BMI from the point of diagnosis, 2) time and type of case 
detection, and 3) treatment outcomes with FLD and SLD. Multivariate binary 
logistic regression analysis was used in the study I to identify the difference 
between the periods for the overall number of smear-positive cases, RIF-resis-
tant cases, and those with BMI<18.5 kg/m2 at the diagnosis, as well as to 
identify the difference between the periods for the number of smear-positive 
cases, RIF-resistant cases, and those with BMI<18.5 kg/m2 detected by mass 
screening and passive case finding. Univariate binary logistic regression ana-
lysis was used to assess the difference for the overall number of cases success-
fully treated with FLD or SLD, as well as to assess the difference for the 
number of cases detected by mass screening or passive case finding and suc-
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cessfully treated with FLD or SLD. Multivariate binary logistic regression ana-
lysis was applied to compare the results of treatment with FLD and SLD 
between patients, whose disease was detected by passive case finding and those, 
who were diagnosed as having TB with the mass screening within the pre-
interventional period. In parallel, multivariate multinomial logistic regression 
analysis was used to compare the respective treatment results between cases 
detected with the entry screening at the non-TB prison hospital, by passive case 
finding, and with mass screening during the post-interventional period. 
In the study II, Pearson’s chi-square test was used for comparison between 
the proportions of discordant results obtained with Xpert MTB/RIF and MGIT 
done on sequential sputum samples versus the same sputum sample, as well as 
to reveal the associations of discordant RIF-susceptibility results and treatment 
outcomes with the presence of various rpoB mutations. Mantel-Haenszel test 
was used to identify the contribution of the mutations, the treatment delay, and 
the different treatments to the treatment outcomes. Individuals with the treat-
ment outcome “lost-to-follow-up” were excluded from the analysis (II). 
The following groups of variables were recorded and analyzed in the study 
III: 1) TB treatment-related variables including chest radiography results at start 
of treatment (expressed as no changes, cavitation, infiltrate, tuberculoma, 
pleurisy, miliary TB, or lung cirrhosis) and follow-up at 6th, 12th, 18th, and 24th 
months of treatment, monthly bacteriological results during the treatment 
course, DST results to INH, RIF, ETH, Z, SM, OFX, MFX, AM, CM, PTO, CS, 
and PAS at the start of the treatment, as well as added resistance to these drugs 
at 6th, 12th, 18th, and 24th months of treatment, the previous history of TB treat-
ment, drugs used in the treatment regimen, adverse events of the ATM on the 
6th, 12th, 18th, and 24th month of treatment, the number of effective drugs and 
number of effective bactericidal drugs at the start of treatment, as well as at the 
6th, 12th, 18th, and 24th month of treatment and 2) clinical and demographic 
variables, such as age, gender, marital status, details on smoking, history of 
illicit drug use, the level of education, stay in pre-trial or penitentiary facility 
with the number of imprisonments, BMI, HIV, and the presence of diabetes 
mellitus. Only one patient had treatment outcome “completed” and was merged 
with the group of “cured” for analyses. Univariate logistic regression analysis 
with Wald’s statistical criteria was used to calculate odds ratios (ORs) and to 
determine the factors associated with cure of RR-TB. Variables with a p-value 
≤0.05 in univariate analysis were used to build the two multivariate models for 
multivariate analysis with backward elimination method to determine the 
factors associated with cure of RR-TB: 1) treatment-related variables and 2) 
clinical and demographic variables.  
Statistical analysis for the whole study (I–III) was performed using STATA 
SE software (version 12, StataCorp, College Station, TX, USA) (165). p-values 




This section summarizes the main results of the studies I–III. The study I 
addressed the impact of addition of the rapid tests for TB to the systematic 
screening on the burden of TB in high-incidence prisons of Azerbaijan. The 
study II measured the discordance between the RIF-susceptibility results by 
Xpert MTB/RIF and MGIT and evaluated whether the application of both tests 
to the same sample affects the discrepancy, but also assessed the treatment 
outcome in patients with the discordant strains. In the study III, the predictors of 




5.1. Impact of the introduction of rapid tests  
to systematic mass screening and passive case finding on 
the burden of tuberculosis in Azerbaijan prisons with  
a special emphasis on rifampicin-resistance (I) 
A total of 2,315 patients with TB were identified in the prisons of Azerbaijan 
during the period of the study I: 1,799 (77.7%) new and 516 (22.3%) relapse 
cases, respectively. Among these, 1,032 (44.6%) were smear-positive, 307 
(13.3%) were RIF-resistant, and 380 (16.4%) occurred among individuals with 
BMI<18.5 kg/m2 at the diagnosis (I). 
During the pre-intervention period (during 2009–2011), 709 out of 1,280 TB 
patients (55.4%) were identified by passive case finding, while the remainder 
(571 patients, 44.6%) were identified through the mass screening (Table 1). Out 
of the 1,280 TB patients identified during the pre-intervention period, 1,162 
(91%) were bacteriologically confirmed and among them, 556 (48%) were 
identified by mass screening and 606 (52%) by passive case finding. During the 
post-intervention period (period during 2012–2015), 1,035 TB patients were 
detected: 445 (42.9%) by passive case finding, 469 (45.3%) by mass screening, 
and 121 (11.7%) by screening at entry to the non-TB prison hospital. Out of the 
1,035 TB patients identified during the post-intervention period, 1,025 (99%) 
were bacteriologically confirmed and among them, 465 (45%) were identified 
by mass screening, 439 (43%) by passive case finding, and 121 (12%) by 
screening at their entry to the non-TB prison hospital. The bacteriological con-
firmation rate achieved during the post-intervention period was significantly 
higher than that during the pre-intervention period (p<0.001, Table 1) referring 
to the higher sensitivity of the supplemented diagnostic algorithm in terms of 
detecting bacteriologically positive TB. During the post-intervention period, 
there were significant linear trends towards decrease in the annual rates of the 
notified (p=0.009), smear-positive (p=0.011), and RIF-resistant TB cases 
(p=0.02). The annual rates of decrease (95% confidence limits) were -435  
(-614; -255), -356 (-517; -195), and -99 (-160; -38), respectively (Figure 2). No 
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significant trends were present for any of these variables during the pre-inter-




Figure 2. Annually notified cases of tuberculosis (TB), smear-positive TB cases, rifam-
picin (RIF)-resistant cases and those with body mass index (BMI) below 18.5 kg/m2 at 
identification in the prisons of Azerbaijan between 01.01.2009 and 31.12.2015, 
presented as rates per 100,000 prisoners. Adopted and reproduced with permission from 
the publisher (I). 
 
 
During the post-interventional period, the overall number of smear-positive 
cases and those with RIF-resistance decreased significantly [adjusted odds ratio 
(aOR)=0.80, 95% confidence interval (CI): 0.68–0.96 and aOR=0.66, 95% CI: 
0.51–0.85, respectively], while the number of cases with BMI ≤18.5 kg/m2 did 
not change (Table 1) (I). 
Compared to that, what was evident during the pre-interventional period, the 
treatment success with FLD during the post-interventional period was signi-
ficantly higher among all cases, among the cases, which were detected by mass 
screening, and among those cases, which were detected by passive case finding 
(aOR=1.93, 95% CI: 1.49–2.50, aOR=3.60, 95% CI: 2.14–7.06, and aOR=1.90, 
95% CI: 1.32–2.74, respectively) (Table 2) (I). No significant difference 
between the number of cases identified by either mass screening or passive case 
finding and successfully treated with SLD were identified, when the pre-
interventional and post-interventional periods were compared (Table 2) (I). 
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Distinctly, when the data were analyzed within both study periods, it was found 
that the cases identified via passive case finding had significantly lower chances 
for treatment success with FLD, compared to those, identified via mass 
screening (aOR=0.50, 95% CI: 0.38–0.67 and aOR=0.31, 95% CI: 0.17–0.57, 
for the pre-interventional and the post-interventional period, respectively), even 
after adjustment for smear-positivity, RIF-resistance, and BMI ≤18.5 kg/m2 
(Table 3) (I). The cases detected by the entry screening during the post-
interventional period had also significantly lower chances for treatment success 
with FLD than did the cases identified by mass screening (aOR=0.16, 95% CI: 
0.17–0.57) (Table 3) (I). Simultaneously, no significant difference for the 
number of cases identified by various types of case finding and successfully 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.2. The prevalence, characteristics, and significance of 
discordant rifampicin-susceptibility results (II) 
The study II included specimens from 532 patients; all specimens had RIF-





Figure 3. Flowchart of samples from patients with tuberculosis diagnosed in the prisons 
of Azerbaijan (2010–2015, n=532) that were included into the study II. MGIT=Myco-
bacteria growth indicator tube; MTB=Mycobacterium tuberculosis, RIF=Rifampicin. 
Reproduced with permission from the publisher (II). 
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Out of the 286 patients in whom the Xpert MTB/RIF- and MGIT-based DST 
were done on sequential sputum samples, 19 (6.6%) demonstrated discordant 
RIF-susceptibility results: 6 (2.1%) were RIF-resistant on MGIT-based DST 
and RIF-susceptible on Xpert MTB/RIF and 13 (4.6%) were RIF-susceptible on 
MGIT-based DST and RIF-resistant on Xpert MTB/RIF (II). Of these 19 iso-
lates showing up discordant results, 12 (63.4%) were from new cases, 6 (31.6%) 
were from cases after loss-to-follow-up, and 1 (5.3%) was from relapse cases 
(II). Out of a total 246 patients in whom the Xpert MTB/RIF and MGIT tests 
were performed from the same specimen, 14 (5.7%) had discordant RIF-
susceptibility results: 4 (1.6%) were RIF-resistant on MGIT-based DST and 
RIF-susceptible on Xpert MTB/RIF and 10 (4.1%) were RIF-susceptible on 
MGIT-based DST and RIF-resistant on Xpert MTB/RIF (II). Of these 14 
isolates, 9 (64.3%) were from new cases, 2 (14.3%) from relapse cases, 2 
(14.3%) from cases after loss-to-follow-up, and 1 (7.4%) was from treatment 
after failure. Ultimately, out of the 532 TB patients included into the study, 33 
(6.2%) had discordant RIF-susceptibility results, 94 (17.7%) were RIF-resistant 
and 405 (76.1%) were RIF-susceptible on both Xpert MTB/RIF and MGIT 
(Table 4) (II). No statistically significant association of discordant RIF-suscep-
tibility results with application of both tests on one sample versus sequential 
samples was found (p=0.65). When the samples were retested on LJ solid 
medium with 16 μg/mL and 32 μg/mL RIF, the results were completely con-
cordant (II). 
A total of 32 cultures of the 33 strains with discordant RIF-susceptibility 
results were sequenced except one strain, which did not grow during repeated 
culture in the SNRL in Borstel, Germany. Of the 32 strains, 10 (31.3%) were 
RIF-susceptible on Xpert MTB/RIF, but resistant on MGIT and 22 (68.8%) 
were RIF resistant on Xpert MTB/RIF, but susceptible on MGIT (II). From 
these 32 strains, 14 (43.7%) were wild-type and 18 (56.3%) had mutations in 
the rpoB gene (Table 5) (II). Out of the 18 strains with mutations in the rpoB 
gene, 11 (61.1%), 3 (16.7%), 2 (11.1%), 1 (5.6%), and 1 (5.6%) represented the 
L511P, S531L, D516G, H526D, and H526L mutations, respectively (II). 
Among the discrepant strains, the rpoB mutations were significantly more 
frequently present among those, who appeared RIF-resistant on Xpert MTB/RIF 
in comparison to those, who were RIF-sensitive on Xpert MTB/RIF (p=0.044) 
(II). The presence of the L511P mutation accounted significantly (p=0.006) for 
the discrepancy in the strains, where the RIF-resistance on Xpert MTB/RIF was 
coupled with RIF-sensitivity on MGIT (Table 5) (II). 
When the MGIT-based DST results were used as a reference, the sensitivity, 
specificity, and positive and negative predictive values of Xpert MTB/RIF in 
detection of RIF-resistance on one sample versus that on consequent samples 
were 90%, 96%, 79%, and 98% versus 91%, 93%, 81%, and 97%, respectively 
(II). When rpoB sequencing was used for resolving discordant RIF-suscepti-
bility results by Xpert MTB/RIF and MGIT, the sensitivity, specificity, and 
positive and negative predictive values of Xpert MTB/RIF in detection of RIF-
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susceptibility on one sample versus that on consequent samples were 100%, 
99%, 94%, and 100% versus 96%, 97%, 93%, and 98%, respectively (II). 
The treatment outcomes in 31 patients of the 32 with discordant strains and 
available rpoB gene sequencing (one patient was lost-to-follow-up and was 
excluded from further analysis) were analyzed: 17 (54.8%) were treated with 
FLD and 14 (45.2%) with SLD (Figure 3) (II). Of these patients, 28 (90.3%) 
and 3 (9.7%) had favorable and unfavorable treatment outcomes, respectively. 
When the rpoB-mutant and wild-type strains were analyzed together, no 
statistically significant association of the favorable treatment outcome with the 
strains being RIF-resistant on Xpert MTB/RIF and RIF-sensitive on MGIT and 
being vice versa was found (Table 6). However, Mantel-Haenszel test revealed 
that the treatment outcomes were dependent on the overall presence of the rpoB 
mutations, particularly the L511P, S531L, D516G, H526L, and H526D muta-
tions (p=0.84, p=0.93, p=0.68, p=0.89, p=0.85, and p=0.73 respectively) (II). 
Among the patients with the strains being RIF-sensitive on Xpert MTB/RIF 
and RIF-resistant on MGIT, 70% and 30% were treated with FLD and SLD, 
respectively, whereas treatment with FLD and SLD resulted in 81% and 87% 
favorable outcomes, respectively, in this discrepancy group (Table 6) (II). 
Among the patients with the strains being RIF-resistant on Xpert MTB/RIF and 
RIF-sensitive on MGIT, 38% and 62% were treated with FLD and SLD, 
respectively, that resulted in 100% and 80% favorable outcomes with these 
treatments, respectively. No significant association was identified between the 
type of discrepant resistance and the outcomes of treatment with FLD or SLD or 
any of the mutations (Table 6) (II). After completion of the treatment, patients 
with discordant RIF-susceptibility, who were still on follow-up during the data 
analysis, were examined after two years (II). No relapses were detected. 
There were 7 strains with RIF-resistance on Xpert MTB/RIF and RIF-
susceptibility on MGIT and wild type on rpoB sequencing: 6 and 1 out of them 
started FLD and SLD treatment, respectively. Out of those 6, who started FLD 
treatment, 5 (83.3%) had favorable treatment outcome, while one patient 




Table 4. RIF-susceptibility results by Xpert MTB/RIF and MGIT of the patients diag-
nosed as having either new or repeated episode of TB managed in the prisons of Azer-
baijan, 2010–2015 (n=532). Reproduced with permission from the publisher (II). 
 
 Susceptible Resistant Total 
MGIT    
Susceptible  405 (76.1) 23 (4.3) 428 (80.4) 
Resistant  10 (1.9) 94 (17.7) 104 (19.6) 
Total  415 (78.0) 117 (22.0) 532 (100.0) 
MGIT=Mycobacteria growth indicator tube; MTB=Mycobacterium tuberculosis; 
RIF=rifampicin; TB=tuberculosis.  




Table 5. RpoB gene sequencing of the 32 strains with discordant RIF-susceptibility 
results detected by Xpert MTB/RIF and MGIT in the patients diagnosed as having 
either new or repeated episode of TB managed in the prisons of Azerbaijan, 2010–2015 
(n=532). Reproduced with permission from the publisher (II). 
 
Type of strain Total RIF sensitive on 
Xpert MTB/RIF, 
but resistant on 
MGIT 
RIF resistant on 
Xpert MTB/RIF, 
but sensitive on 
MGIT 
p-valuea 
Mutant strains  18 (56.3) 3 (30.0) 15 (68.2) 0.04 
L511P  11 (61.b) 0 (0.0c) 11 (73.3d) 0.01 
S531L  3 (16.7b) 2 (66.7c) 1 (6.7d) 0.16 
D516G  2 (11.1b) 0 (0.0c) 2 (13.3d) 0.32 
H526L  1 (5.5b) 0 (0.0c) 1 (6.7d) 0.49 
H526D  1 (5.5b) 1 (33.3c) 0 (0.0d) 0.13 
Wild-type strains  14 (43.7) 7 (70.0) 7 (31.8) 0.04 
Total  32 (100.0) 10 (100.0) 22 (100.0)  
MGIT=Mycobacteria growth indicator tube; MTB=Mycobacterium tuberculosis; RIF= 
rifampicin; TB=tuberculosis. 
Data are presented as numbers (%). 
aSignifies comparisons between the strains being rifampicin-susceptible on Xpert 
MTB/RIF, but resistant on MGIT and between those being rifampicin-resistant on Xpert 
MTB/RIF, but sensitive on MGIT done on strains with various mutations, as well as on 
wild-type strains (Pearson’s chi-square test). bDenominator used for calculation of the 
proportion was 18. cDenominator used for calculation of the proportion was 3. dDeno-






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3. Treatment regimen-related predictors of cure in 
rifampicin-resistant tuberculosis in the prison settings 
with low loss-to-follow-up (III) 
A total of 612 patients with pulmonary DR-TB were diagnosed in the Azer-
baijan PS during the period of the study III (Figure 4). 
 
 
Figure 4. Flowchart of patients with pulmonary RR-TB, who started treatment in the 
prisons of Azerbaijan during 01.04.2007–28.02.2013 and were included into the study 
III. DR-TB=drug-resistant tuberculosis; SLD=second-line anti-tuberculosis drugs; 
TB=tuberculosis. Reprinted with permission from the International Union Against 
Tuberculosis and Lung Disease. Copyright © The Union (Gurbanova E, Mehdiyev R, 
Blondal K, Altraja A. Predictors of cure in rifampicin-resistant tuberculosis in prison 
settings with low loss to follow-up. Int J Tuberc Lung Dis. 2016;20(5):645–51.) (III). 
 
 
Out of them, 529 (86.4%) started treatment with SLD and 444 (72.6%) had RR-
TB. Of these 444 patients with RR-TB, 78.4% were cured, 9.2% experienced 
treatment failure, 6.1% dead, and 6.3% were lost to follow-up (Table 7). The 
cure rate among the new and retreatment patients was 83.4% and 77.5%, 
respectively, whereas the cure rate among those patients with RIF mono-
resistance was 100%, but was 80.3% in MDR-TB, 73.8% in pre-XDR-TB, and 
20% in XDR-TB (Table 7) (III). Out of the all RR-TB patients, the vast 
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majority (442, 98.5%) consisted of males with mean age 38.0 years (range 18–
63 years) (III). The mean number of ATM to which the cases had resistance at 
the commencement of the treatment was 5.2 (range, 110). The mean duration 
of treatment among those patients who were “cured” and had “poor treatment 
outcome” was 21.7 months (range 12.436.6 months) and 13.3 (range 0.1–35.2 
months) respectively (III). The drugs used for treatment of patients with RR-TB 
included EMB (47 patients; 10.6%), Z (257; 57.9%), OFX (147; 33.1%), LFX 
(226; 50.9%), MFX (27; 6.1%), AM (110; 24.8%), CM (224; 50.5%), PTO 
(393; 88.5%), CS (416; 93.7%), and PAS (414; 93.2%). 
Larger number of effective bactericidal drugs, including FQ and second-line 
injectables, in the regimen at 7th–12th and 13th-18th months significantly in-
creased the chances for cure in all patients (aOR=2.29, p=0.045 and aOR=4.39, 
p=0.014, respectively), as well as among the retreatment cases (aOR=3.88, 
p=0.033 and aOR=5.02, p=0.011, respectively) (Table 8). Longer duration of 
treatment was significantly associated with cure among the retreatment cases 
(aOR=1.17, p=0.029), as well as in all patients (aOR=1.18, p=0.022). The 
inclusion of LFX into the treatment regimen increased the chances for cure in 
all patients (aOR=4.25, p=0.021). Normal chest X-ray at the start of treatment 
on one hand and healing of cavitation latest by the 12th month of treatment on 
the other were significantly associated with cure in all patients (aOR=1.98, 
p=0.014 and OR=7.17, p<0.001), respectively, but also in the retreatment cases 
(aOR=2.26, p=0.011 and aOR=6.79, p<0.001, respectively). The patients with 
BMI ≥18.5 at treatment start had significantly higher cure rates in all, as well as 
in the retreatment cases (aOR=1.97, p=0.019 and aOR=1.90, p=0.039, respec-
tively) (III). 
On the contrary, added resistance to CM during the treatment significantly 
decreased the chances for cure in all cases and among the retreatment patients 
(aOR=0.23, p=0.04 and aOR=0.22, p=0.045, respectively) (III). Loss of hearing 
was also significantly associated with lower cure rates in all and in the retreat-
ment patients (aOR=0.18, p=0.003 and aOR=0.14, p=0.001, respectively). 
Release from prison before completion of the treatment course significantly 
diminished the probability of cure in all and in retreatment patients (aOR=0.43, 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The studies I–III evaluated the impact of the WHO-recommended systematic 
screening, diagnostics, and treatment to TB and M/XDR-TB burden in the high 
burden and low-default prison settings and defined several specific aspects of 
this impact. 
The main finding in the study I is that the introduction of the rapid tests like 
liquid culture and Xpert MTB/RIF to the algorithms of systematic screening for 
TB in prisons significantly increased their sensitivity to detect bacteriologically 
positive TB cases and lead to 3-, 10-, and 5-fold decrease in the annual rates of 
all notified, smear-positive, and RIF-resistant TB cases, respectively, within a 
short period of time (Table 1). It has been formerly described that mass incarce-
ration inevitably leading to overcrowding, poor screening practices with delayed 
detection, and inadequate treatment contribute to high TB rates in prisons (16, 
60). Georgia, the country bordering Azerbaijan with similar background TB 
situation, kept reporting increasing TB rates in prisons acknowledging a lack of 
systematic screening with rapid tests until the wide amnesty took place in 2012–
2013 that lead to 2.3-fold decrease of prison population. As a result, drastic 
decrease of TB incidence and prevalence among inmates occurred (166, 167). 
We assume that in our study, the significant decrease of TB rates in prisons was 
due to enhanced systematic screening, since the major factors that could other-
wise influence the rates. i. e. the size of the prison population, screening covera-
ge, treatment strategies, and infrastructure of prisons, remained stable during the 
study period. Our finding of no significant trends towards decrease of the TB 
burden in prisons prior to this intervention (I) may be considered as an additio-
nal efficacy argument in favor of the improved practice introduced into the PS. 
The study is unique, as it provides practical evidence to recommend usage of 
the rapid tests for systematic screening in prisons (I). Formerly, due to the very 
limited introduction of the rapid tests in penitentiaries, this kind of recommen-
dations were mainly based on logical assumptions and mathematical modeling 
(19, 20, 74, 87). The dynamic transmission model of TB and MDR-TB epide-
mics in prisons of the former Soviet Union showed only 14% and 12% decrease 
in the prevalence of TB and MDR-TB, respectively, after 5 years of the annual 
screening with the implementation of Xpert MTB/RIF in similar settings (87). 
Our finding of many-fold decrease of the TB rates during a four-year period (I) 
clearly surpassed the predictions of the mathematical modeling (87). Moreover, 
our study I showed that the WHO-recommended systematic screening works 
effectively only if coupled with rapid tests, since significant linear trends 
towards decrease in the annual TB rates were identified only after introduction 
of rapid tests into the screening algorithms (I). Bearing in mind that each smear-
positive case can infect approximately 10–15 persons annually (52, 53), the role 
of highly sensitive screening algorithms in decreasing the TB transmission is 
inevitable, which is especially critical in settings of high proportion of RR-TB 
(52, 53). Taking into account that the size of the prison population was stable 
52 
during the period of our current study (I), the significant linear trends towards 
decrease in the TB rates after introduction of the rapid tests assume also 
reduction of TB transmission (I).  
Our study also identified improved outcomes of FLD treatment after intro-
duction of Xpert MTB/RIF and liquid culture to the systematic screening algo-
rithms in prisons (I). Specifically, the cases detected by mass screening had 
better outcomes of treatment with FLD than did those, whose disease was iden-
tified by passive case finding (I). Since the clinical symptoms that urge an 
inmate to seek for health care serve as the trigger for passive case finding, the 
benefit of mass screening on the outcomes of the treatment with FLD shown in 
our study (I) may be explained by the detection of TB at earlier stages with 
characteristically less or no symptoms, with smear-negativity, or with a BMI 
over 18.5 kg/m2 (168, 169). Along with the evidence from elsewhere that con-
firms the cost effectiveness of mass screening in prisons (76), our finding sup-
ports the routine use of rapid test-coupled mass screening among inmates (I). 
Only little empirical evidence of the benefit from screening without rapid 
tests to TB notification and treatment outcomes has been reported (78). The 
results obtained during the pre-interventional period of the current study (I) 
obviously support this conclusion. Further data on the routine use of rapid tests 
for systematic screening in prisons are especially needed to advocate and 
accelerate the uptake of new rapid diagnostic technologies in prisons. Collec-
tively, our findings (I) suggest sound arguments for informed decision on intro-
duction of rapid diagnostic tests into the systematic screening algorithms in 
analogous settings worldwide. Since the baseline TB notification rate in the 
Azerbaijan prisons was similar to the rates reported by correctional facilities of 
other high-TB/RR-TB-burden countries, our results evoke reproducibility (10).  
Undesirably, the overall outcomes of the treatment with SLD did not 
significantly change over time in our study (I). Practically, this finding appeals 
to an urgent need to ensure accelerated access to new and/or repurposed ATM 
in prisons to allow improved treatment outcomes of the cases with extensive 
drug-resistance (170). 
The study II revealed that the proportion of obtained discordant RIF-
susceptibility results is almost equal regardless of whether both Xpert MTB/RIF 
and MGIT are applied on the same sputum sample or on sequential samples. 
While the WHO recommends having at least two sputum samples tested, as 
well as having Xpert MTB/RIF and liquid culture based DST done for the 
diagnostic purposes (171), our finding suggest that the TB programmes may 
build their diagnostic algorithms using Xpert MTB/RIF and MGIT on sequen-
tial sputum samples without expecting a significant increase of the level of 
discrepant RIF-susceptibility results, thus, avoiding an additional practical 
difficulties to get enough sputum for using both tests on the same sample (103). 
In our study, the number of discrepant strains at the group with RIF-resis-
tance on Xpert MTB/RIF and RIF-sensitive on MGIT was more than twice of 
those, who were RIF-sensitive on Xpert MTB/RIF and RIF-resistant on MGIT 
(II). The presence of the L511P mutation, found previously in both RIF-
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susceptible and -resistant isolates by various WHO-endorsed methods (172, 
173), appeared to significantly contribute to the discrepancy in our isolates (II). 
Although our study protocol did not include measurement of minimum inhibi-
tory concentration (MIC) for RIF (II), several other studies have shown that the 
MICs for RIF in isolates harboring L511P mutation was 4–10 times below the 
standard critical breakpoint resulting in susceptibility according to the culture-
based DST (174–177). Rigouts et al. indicated that along with some other rpoB 
mutations, the L511P mutation is prone to be missed by MGIT (178). Another 
study found that L511P mutation has a weak association with phenotypic drug-
resistance of M. tuberculosis (179). We did not identify any significant associa-
tion between the outcomes of treatment with FLD or SLD and either the certain 
mutations or the type of discrepant resistance (II). These results may also 
suggest that the clinical relevance of the mutations on one hand and the pattern 
of discrepant resistance on the other may be insignificant (II). As a matter of 
fact, the latter treatment issue, however, needs further corroboration. 
Our finding that 70% of the discordant strains with RIF-sensitivity on Xpert 
MTB/RIF, but RIF-resistance on MGIT did not have mutations at the rpoB 81-
bp region (II) suggests that in discordant strains, the prevalence of isolates with 
mutations outside the hot spot region and whose RIF-resistance is thus non-
detectable with Xpert MTB/RIF may be above the formerly reported 2–5% 
(115, 116). Still, our results on the sensitivity and specificity of Xpert MTB/RIF 
in the detection of RIF-resistance (II) were concordant with the results of a 
recent meta-analysis (105) that reported 95% sensitivity (95% CI 90–97%) and 
99% specificity (95% CI 97–99%). Moreover, as said, our results (II) suggest 
that the sensitivity, specificity, and positive and negative predictive values of 
Xpert MTB/RIF in detection of RIF-resistance are similar, when Xpert 
MTB/RIF and MGIT were used on one sample or sequential samples. Among 
the strains identified in our study (II), 1.3% were found to be RIF-resistant on 
Xpert MTB/RIF, RIF-sensitive on MGIT, and wild type on rpoB sequencing, 
which fits into the accepted specificity of Xpert MTB/RIF performance in the 
detection of RIF-resistance (105).  
Since we were able to demonstrate that RIF-susceptibility results by mole-
cular and phenotypic tests in high-RR-TB-burden settings are prone to about 
6% discrepancy (II), the clinicians should be aware that the preliminary result 
reported by the molecular test may be dissonant with the subsequently reported 
culture-based DST. Erroneous RIF-susceptibility results may lead to either 
treatment of the RR-TB patient with ineffective standard FLD regimen on one 
hand or unnecessary treatment of RIF-sensitive TB patient for up to 20 months 
with SLD on the other (180). There are recommendations available from the 
Clinical Laboratory Standards Institute, European Committee on Antimicrobial 
Susceptibility Testing, as well as from the WHO that in cases of the discrepant 
RIF-resistance results, the testing should be repeated or the culture isolates 
should be referred further for DNA sequencing (162, 181). However, these 
procedures are time-consuming and not always feasible from programs’ and 
patients’ point of view. In our study (II), among the patients with the discrepant 
54 
RIF-resistance results, the treatment outcomes did not significantly differ 
between those, who received FLD and those, who received SLD. However, in 
the high-RR-TB-burden settings and in cases of uncertainty about the RIF-
susceptibility, it may be justified that the clinical decision to initiate SLD 
treatment until the RIF-resistance is determined by additional repeated tests. 
In conclusion, in addition to the aspects discussed above, the study II is uni-
que in terms of at least three matters: it reports the largest number of discordant 
strains, it is performed in high-burden TB/RR-TB prisoners’ population, and it 
evaluates treatment outcomes of patients with discordant strains in a low loss-
to-follow-up setting. 
The main finding of the study III was that the cure rate in RR-TB decreased 
along with the decrease in the number of effective drugs with high bactericidal 
activity in the treatment regimen after the 6th month of treatment. Usually, 
decrease in the number of effective ATM is a result of the development of 
resistance to the respective medicines, treatment-associated adverse events, or 
discontinuation of the second-line injectables after the intensive phase of 
treatment. In our study (III), out of the adverse events to the ATM, only loss of 
hearing that lead to permanent exclusion of second-line injectable was 
associated with lower chances of cure indicating that ATM-associated adverse 
events that lead to discontinuation of a particular drug may have a decisive 
significance. We found that the longer the patients were treated with higher 
number of bactericidal ATM, the better were the chances of cure (III). While 
the pivotal importance of inclusion of bactericidal ATM has been described 
already by Mitchison in a paper on the short-course chemotherapy (151), the 
role of bactericidal ATM seems to be under-recognized in the treatment of RR-
TB nowadays, as drugs with such activity may be rightfully stopped during the 
course of treatment (146). Until recently, the number of bactericidal ATM in the 
regimens was compromised due to the recommendation to discontinue second-
line injectable after the first eight months of treatment, so-called “intensive 
phase of treatment” (102). Currently, the WHO revised its approach to the 
design of RR-TB treatment ensuring maximal number of bactericidal agents at 
the treatment initiation (152). However, still the number of drugs with high 
bactericidal activity is assumed to be decreased during the course of treatment. 
This can be related to e.g. the limitation of the use of BDQ and DLM to the first 
six month of treatment, referring to the lack of safety data on the use of these 
drugs beyond six months (152). Taken together, there is a need for studies 
evaluating the safety of prolonged use of BDQ and DLM, so to ensure sustained 
strength of RR-TB regimens throughout the treatment course. 
Our study (III) allowed focusing more comprehensively on the analyses of 
medical rather than adherence-related determinants of cure. Despite the high 
prevalence of patients with pre-XDR-TB and XDR-TB, the proportion of all 
cured patients with RR-TB was exceptionally high in our study (III) and safely 
exceeded the target level of at least 75% set by WHO (22). This high cure rate 
may be, in part, due to the diligent implementation of the WHO-recommended 
TB control strategies and support provided to the patients during the treatment 
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(25, 182). However, one cannot exclude that this may also purely indicate the 
role of the low loss-to-follow-up rate 
Conversely, one could not purposely neglect the role of specific prison-
related factors, such as the type or term of sentence or the number of previous 
imprisonments onto the results obtained (III). But since these contributors did 
not significantly influence to treatment outcomes of the patients with RR-TB in 
this study (III), our prison model appears to be valid enough to bring realis-
tically forward the significance of proper drug treatment. Regrettably, when the 
prisoners were released during their treatment, then the chances to be cured 
decreased in comparison to those, who completed their whole treatment in the 
prison. Binswanger et al. has assumed that the socioeconomic challenges and 
enticements the ex-prisoners face after release are the confounders that may 
contribute to the lower cure rates (183). This leads to a conclusion that special 
attention should be paid to released prisoners with active TB disease, so to 
enable uninterrupted treatment and favorable treatment outcomes.  
In our study, the RR-TB patients with BMI ≥18.5 kg/m2 and normal chest x-
ray at the time of the diagnosis had significantly higher chances for cure (III). 
However, we also found that the cure was still likely in the RR-TB patients with 
radiological improvement that occurred no later than by the 12th month. These 
are additional arguments in favor of critical role of rapid TB diagnostics and 
sound treatment throughout the course in attainment high cure rates among the 
patients with RR-TB.  
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7. CONCLUSIONS 
I. The introduction of rapid diagnostic tests into the algorithms of systematic 
screening for active TB leads to a significant decline in the overall TB rate, 
smear-positivity rate, and RIF-resistance rate in high-TB-burden prison 
settings, as well as significantly improves the outcome of treatment with 
FLD. 
 
II. The Xpert MTB/RIF and MGIT testing may be used in sequential sputum 
samples in diagnostic algorithms, since the rate of discordant RIF-
susceptibility results is independent on whether the same sample or 
sequential samples are used. The most frequently observed pattern of 
discordant results includes RIF-resistance by Xpert MTB/RIF and RIF-
sensitivity on MGIT and is mainly due to the L511P mutation, whose 
clinical relevance in terms of determining RR may be insignificant. 
However, the clinicians should be aware of certain discrepancy between 
the results of molecular and phenotypic tests and should consider SLD 
treatment with further adjustment after RIF-susceptibility of M. tuber-
culosis is determined. 
 
III. The use of higher number of effective bactericidal drugs after the 6th month 
of the course of treatment of RR-TB is the main factor associated with 
cure. The patients released from PS before completion of the full course of 
treatment require additional support to increase patients’ chances for cure. 
Enrolment to treatment with no radiological signs of TB and with BMI 
≥18.5 kg/m2 considerably increases the possibility of cure, prompting rapid 
diagnostics of TB. The level of treatment interruption among RR-TB 




8. FUTURE RESEARCH 
1. Evaluation of the actual problem of LTBI among prisoners and assessment of 
the quality of the LTBI-related care provided to the prisoners in comparison 
with the civil population. 
 
2. Evaluation of the effectiveness and safety of the treatment of the RR-TB 
patients with the novel drugs beyond 24 weeks. 
 
3. Evaluation of the effectiveness and safety of the treatment of the RR-TB 
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SUMMARY IN ESTONIAN 
Tuberkuloosi iseärasused madala ravikatkestamise,  
kuid kõrge ravimresistentsusega iseloomustuvates 
vanglatingimuses 
Tuberkuloos (TB) on nakkushaigus, mida põhjustavad Mycobacterium tuber-
culosis’e kompleksi kuuluvad mükobakterite liigid. Tuberkuloosinakkuse üle-
kanne toimub piisknakkuse teel aktiivset kopsutuberkuloosi põdevatelt inimes-
telt õhuga kanduvate piisktuumade vahendusel. Haige eritab haigustekitajaid 
köhimise, aevastamise või rääkimise käigus tekkivate sekreedipiiskadega, mis 
kuivavad piisktuumadeks ja püsivad õhus ning satuvad seejärel terve inimese 
hingamisteedesse. Nakkusprotsessi käigus kujunev haigus haarab kõige sage-
damini kopse ja tekkind haigust nimetatakse kopsutuberkuloosiks. Kopsutuber-
kuloosi sümptomiteks on krooniline köha, kehakaalu vähenemine, isukaotus ja 
üldine halb enesetunne. Maailma Terviseorganisatsiooni (MTO) andmetel hai-
gestus 2017. aastal TB-i 10 miljonit inimest ja suri 1,3 miljonit inimest. Ligi-
kaudu 95% TB-i juhtudest on seotud arengumaadega ja ligemale üks üheksast 
uuest TB-juhust esineb inimestel, kes on nakatunud inimese immuunpuudulik-
kuse viirusega (HIV). TB on kümnes juhtiv surmapõhjus kogu maailmas ning 
alates 2011. aastast on TB olnud üks peamistest surmapõhjustest HIV infekt-
siooni ja omandatud immuunpuudulikkuse sündroomi (AIDS) põdevate inimes-
te seas. TB-i haigestunud isikute seas esineb kõrge suremus hoolimata asjaolust, 
et õigeaegse diagnoostika ja korrektse ravi korral on enamik tuberkuloosijuhtu-
dest ravitavad. 
Ravimresistentne tuberkuloos, mis reeglina on kas ebaõnnestunud ravi või 
ravimresistentse tüvega nakatumise tulemus, on jätkuvalt paljudes riikides suur 
rahvatervise probleem. Maailma kõige vaesemates piirkondades ja riskirühma-
des, sealhulgas kinnipeetavate seas, on laialt levinud multiresistentne tuberku-
loos (MDR-TB). MDR-TB on defineeritud kui TB, mille haigustekitajal on 
laboratoorselt kinnitatud resistentsus kahe kõige tugevama esimese rea ravimi, 
isoniasiidi (INH) ja rifampitsiini (RIF) suhtes. MTO andmetel registreeriti 2017. 
aastal 558 000 uut rifampitsiiniresistset (RR) TB-i juhtu, millest 82% oli MDR-
TB. 2017. aastal oli MDR-TB ja RR-TB haigusjuhtude osakaal kokku hinnan-
guliselt 3,5% uutest ja 18% varem ravitud juhtudest. Seejuures on märkimis-
väärne, et suurima osakaaluga (>50%-l varem ravitud juhtudest) oli MDR/RR-
TB endise Nõukogude Liidu vabariikides. 2017. aastal moodustas MDR-TB 
juhtude hulgast hinnanguliselt 8,5% nn. eriti resistentne TB (XDR-TB), mis on 
defineeritud kui MDR-TB, mille haigustekitajal on täiendav resistentsus lisaks 
vähemalt ühe fluorokinolooni ja vähemalt ühe süstitava teise rea TB-vastase 
ravimi (amikatsiini, kanamütsiini või kapreomütsiini) suhtes. Esimesed XDR-
TB-i juhtumid registreeriti 2006. aastal, 2017. aasta lõpuks oli neid registree-
ritud juba 127 riigis.  
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Suureks probleemiks on TB-i aladiagnoosimine. Hinnangulistest jäi 2017. 
aastal 36% TB-i ja 71% MDR/RR-TB-i juhtudest diagnoosimata. Aladiagnoo-
simine tuleneb peamiselt TB-i alasest teadmatusest, eriti inimeste seas, kellel on 
halb juurdepääs tervishoiuteenustele, näiteks kinnipeetavatel. Hinnanguliselt 
paikneb üle maailma igal hetkel kinnipidamisasutustes üle 10 miljoni inimese. 
TB-i esinemissagedus vanglas viibivate inimeste seas on 1,5–28,1 korda kõr-
gem kui tavaelanikkonna hulgas. Riskitegurid, mis soodustavad kinnipidamis-
asutustes TB-i haigestumist, on pikaajaline viibimine ülerahvastatud ja halva 
ventilatsiooniga ruumides, HIV-infektsioon, alatoitumus, diabeet, suitsetamine 
ja alkoholi tarbimine ning ebaseaduslik uimastitarbimine, kuid ka eelnev TB. 
Eriti kõrget ravimiresistentse TB-i esinemissagedust kinnipidamisasutustes 
täheldatakse endise Nõukogude Liidu vabariikides. Üheks kriitiliseks TB-i 
tõrjet takistavaks asjaoluks vanglates on piiratud ligipääs varasele ja kõrgekvali-
teedilisele TB-i diagnostikale tingituna halvasti korraldatud profülaktilisest läbi-
vaatusest, diagnostiliste algoritmide puudulikkusest ja laboratoorsete vahendite 
puudumisest. Diagnostika ja ravi viibimine võib veelgi suurendada TB-i 
nakkuse ülekande riski ja tõsta ebasoodsa ravitulemuse tõenäosust. TB-i haiges-
tumise vähendamiseks kinnipidamisasutustes soovitab MTO süstemaatiliselt 
läbi viia nii aktiivset ehk nn. massilist sõeluuringut kui ka passiivset juhtude 
avastamist kinnipeetavate seas. Passiivse juhtude avastamise korral eeldatakse, 
et haige pöördub ise sümptomitega tervishoiutöötaja või tervishoiuteenuse 
poole. Samas soovitatakse TB-tõrjeprogrammidel kasutada diagnostilisi kiir-
teste, nagu seda on Xpert MTB/RIF ja bakterite kultiveerimine vedelsöötmetes. 
Kuigi kinnipidamisasutustes võiksid tänu võimalustele patsientide ravikatkes-
tusi vältida olla tuberkuloosikontrolli seisukohalt ideaalilähedased tingimused, 
on MTO poolt eesmärgiks seatud 75%-ne raviefektiivsus seal harva saavutatav. 
Ravi katkestamine on üks peamisi ravitulemusi negatiivselt mõjutavaid tegu-
reid, kuid ei pretendeeri seletama kaugeltki mitte kõike, mis on ravi ebaõnnes-
tumise taga.  
1991. aastal, pärast aastakümneid kestnud suhtelist hooletusse jätmist, hakati 
taaselustama ülemaailmseid jõupingutusi tuberkuloosi tõrjeks. Näiteks andis 
Maailma Tervise Assamblee 1991. aastal välja resolutsiooni, millega nimetatud 
organisatsioon tunnistas TB-i üheks peamiseks ülemaailmseks terviseproblee-
miks. Sellest ajast alates on heaks kiidetud mitu TB kontrollistrateegiat, nende 
hulgas ”Otseselt kontrollitava ravi strateegia“ (DOTS), ”Ülemaailmne plaan 
elimineerida TB aastatel 2006–2015” ja praegugi kasutatav strateegia ”Stop 
TB”. Viimati mainitud strateegia ”Stop TB“ eesmärk on vähendada suremust 
TB-i 90% võrra ja tuberkuloosi esinemissagedust 80% võrra aastaks 2030, mis 
võiks aastast haigestumist vähendada 15%-ni ja lõpuks vähendada TB 
esinemissagedust 2050. aastani <1 juhuni miljoni elaniku kohta. Nimetatud ees-
märgi saavutamine eeldab muu hulgas varast diagnostikat, süstemaatilisi sõel-
uuringuid ja tõhusat ravi kõrge riskiga inimrühmades, sealhulgas vangide seas. 
Käesolev uurimistöö viidi läbi Aserbaidžaani Vabariigi kinnipidamisasutus-
tes. Aserbaidžaan kuulub 30 kõige kõrgema RR-TB-i haigestumisega riigi ja 
seetõttu ka 18 TB-i seisukohalt kõrge prioriteediga riigi hulka, mis võitlevad 
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TB-i vastu MTO Euroopa piirkonnas, kus TB-i haigestumus on kinnipeetavate 
seas 18 korda kõrgem kui tsiviilelanikkonna hulgas. Uuringu üldeesmärk oli 
hinnata MTO poolt soovitatava massilise sõeluuringu, diagnostika ja ravi mõju 
TB-i, MDR-TB-i ja XDR-TB-i haigestumisele madala ravikatkestamise, kuid 





I. Hinnata TB-i avastamise meetodite, ühelt poolt massiliste sõeluuringute ja 
teiselt poolt haigusjuhtude passiivse avastamise mõju TB-i haigestumisele 
ja TB/RR-TB ravitulemustele kõrge TB/RR-TB esinemissagedusega Aser-
baidžaani vanglates enne ja pärast kiirdiagnostika kasutuselevõttu. 
 
II. Leida, kas selliste juhtude, kus erinevate määramismeetoditega nagu Xpert 
MTB/RIF kui molekulaarne meetod ja määramine MGIT-kultuurides kui 
nn. fenotüüpiline meetod saadud RIF-tundlikkuse määramistulemused 
lahknevad, esinemissagedus sõltub sellest, kas kasutatakse ühte ja sama 
rögaproovi või järjestikuseid, eri aegadel kogutud rögaproove. Selgitada 
rpoB mutatsioonide esinemist tüvedel, millel RIF-tundlikkuse määramis-
tulemused lahknevad, ning hinnata ravitulemusi vastavate bakteritüvedega 
TB-patsientidel. 
 
III. Kasutades Aserbaidžaani kinnipidamisasutuste eelist, mis seisneb madalas 
ravikatkestajate hulgas, kinnitada hüpoteesi, mille kohaselt ravimtundlik-
kuse testimise tulemustel põhinev individualiseeritud ravi bakteritsiidsete 
ravimite maksimaalse kasutamisega kogu ravikuuri vältel on peamine 
tegur, mis tagab efektiivse ravi RR-TB-iga patsientidel. Paralleelselt hinna-
ta efektiivse ravitulemuse riskitegureid RR-TB-ga patsientide seas rõhu-
asetusega raviskeemidega seotud faktoritele.  
 
 
Patsiendid ja meetodid 
 
Käesolev uurimistöö põhineb kolmel uuringul osaliselt kattuvatel kohortidel, 
mis koosnesid Aserbaidžaani kinnipidamisasutustes diagnoositud TB-i või 
MDR/RR-TB-i juhtudest. Uuringute kohordid ja erinevad ajaperioodid valiti 
vastavalt uuringute konkreetsetele eesmärkidele ja ajastusele. Uuringuproto-
kollile andis kooskõlastuse ja uuringute läbiviimiseks andis loa Aserbaidžaani 
Vabariigi Tervishoiuministeeriumi bioeetika komitee (11. märtsist 2015, Bakuu, 
Aserbaidžaani Vabariik). 
I uuring. 2009. aasta jaanuaris käivitati Aserbaidžaani kinnipidamisasutustes 
iga-aastased massilised sõeluuringud-läbivaatused, mis koosnesid standardisee-
ritud TB küsimustikust viie TB-spetsiifilise küsimusega ja rindkere röntgeni-
ülesvõttest. Kui kas küsimustik või rindkere röntgeniülesvõte viitas TB-ile, 
koguti üks rögaproov mikroskoopiliseks uuringuks. Positiivse mikroskoopilise 
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uuringu tulemuse puhul eraldati vastavad patsiendid ja viidi vangla TB-haig-
lasse edasiseks diagnoosi täpsustamiseks ja raviks. Samal perioodil käivitatud 
haigusjuhtude passiivse avastamise strateegia põhines eeldatavate tuberkuloosi-
juhtude leidmisel >2 nädalat kestnud köha esinemise alusel. Sellised juhud 
isoleeriti ja suunati vangla TB haiglasse edasiseks diagnoosi täpsustamiseks ja 
raviks. I uuringu mõistes oli ajavahemik, mis kestis 2009. aasta jaanuarist kuni 
2011. aasta detsembrini, määratletud kui nn „sekkumiseelne periood“. Alates 
2012. aasta jaanuarist testiti kõikide eeldatavalt TB-haigete rögaproove MGIT 
söötmetel. Eeldatavad TB-i juhud olid tuvastatud sümptomite tõttu pöördumisel 
või kõrvalekallete esinemisel rindkere röntgenogrammidel iga-aastase massi-
kontrolli käigus. Positiivse külvitulemusega patsiendid suunati ravile vangla 
TB-haiglasse. Samal perioodil kasutati TB juhtude passiivse leidmisel järgmisi 
kriteeriume: köha kestusega >2 nädalat, millele järgnes Xpert MTB/RIF ana-
lüüs. Positiivse Xpert MTB/RIF tulemusega patsiendid suunati samuti raviks 
vangla TB-haiglasse. I uuringu puhul nimetati ajavahemikku jaanuarist 2012 
kuni detsembrini 2015 nn. „sekkumisejärgseks perioodiks“ (s.t. perioodiks pä-
rast kiirdiagnostika meetodite – Xpert MTB/RIF analüüsi ja vedelsöötmete – 
kasutuselevõttu). Lisaks kontrolliti „sekkumisjärgsel perioodil“ kinnipeetavaid, 
kes ei asunud TB-osakonnas, standardiseeritud viie sümptomi küsimustiku ja 
rindkere röntgenograafia abil. Juhtudel, kus esines TB-i sümptomeid või tuvas-
tati röntgenograafilisi kõrvalekaldeid, testiti röga Xpert MTB/RIF-iga, millele 
järgnes positiivse testitulemuse korral ravi vangla TB-haiglas. 
II uuring. II uuringus uuriti aastatel 2013–2015 esimest rögaproovi Aser-
baidžaani kinnipidamisasutuste TB-i haigetelt otse Xpert MTB/RIF meetodil 
ning teine rögaproov saadeti külviks ja ravimtundlikkuse määramiseks kasuta-
des MGIT-kultiveerimist. Lisaks kasutati arhiveeritud bakterikultuure (alates 
2010. aastast olid kõik vanglasüsteemi laboris töödeldud positiivsed kultuurid 
külmutatud ja arhiveeritud, sealhulgas MGIT-kultuurid). Xpert MTB/RIF testid 
teostati tagasiulatuvalt, elustades täiendavalt külmutatud tüved MGIT-põhistest 
kultuuridest, mis olid arhiveeritud samade haigete esmase diagnoosimise ajal. 
Xpert MTB/RIF meetodil saadud tulemusi võrreldi eelnevalt teostatud MGIT-
põhiste ravimtundlikkuse testide tulemustega. Tulemuste vasturääkivuse korral 
korrati teste kahe erinevat tehniku poolt. Tüvesid, mis endiselt näitasid vastu-
olulist RIF-tundlikkust, testiti Saksamaal Borsteli Rahvusvahelises Referent-
laboris (SNRL), kus tahketel Löwenstein-Jensen’i sõõtmetel määrati kvantita-
tiivselt RIF-tundlikkus koos minimaalsete inhibeerivate kontsentratsioonide- 
ga ning teostati rpoB geeni sekveneerimine. Lahknevate RIF-tundlikkuse mää-
ramistulemustega patsiente oli ravitud nii esimese kui ka teise rea TB-ravi-
mitega, vastavalt ravimtundlikkuse näitajatele, mis olid määratud ravi alusta-
mise ajal; samuti oli arvestatud eelnevat haiguse anamneesi, kliinilist seisundit 
ning RR-TB-i riski. 
III uuring. Uuringusse kaasati kõik uued ja varasemalt ravitud patsiendid, 
kes alustasid esmakordselt multiresistentse kopsu-TB ravi Aserbaidžaani kinni-
pidamissüsteemis ajavahemikus 2007–2013. Vähemalt 5 TB-vastast ravimit 
sisaldavad ravirežiimid kohandati individuaalselt vastavalt ravimtundlikkusele. 
73 
Ravi teise rea preparaatidega alustati kohe pärast resistentsuse tuvastamist RIF-
ile mistahes meetodil. Ravimeid manustati kogu ravikuuri vältel vähemalt 18 
kuu jooksul otsese jälgimise teel 6 korda nädalas. 
 
 
Peamised tulemused ja järeldused 
 
I. Kiirtestide, nagu vedelkultuuri ja Xpert MTB/RIF kasutuselevõtt TB-i 
diagnostikaalgoritmides süstemaatilisel läbivaatusel Aserbaidžaani vangla-
süsteemis alandas suhteliselt lühikese aja jooksul vastavalt 3-, 10- ja 5-
kordselt kogu TB-i haigestumist, mikroskoopial positiivsete uute juhtude 
esinemissagedust ja RIF-resistentsete juhtude esinemissagedust. Uuring I 
on ainulaadne selle poolest, et pakub tõendeid soovitamaks praktikas TB-i 
kiirtestide kasutuselevõttu vanglates. Varem tugines soovitus kasutada 
kinnipidamisasutustes TB-i kiirteste peamiselt vaid loogilistele eeldustele 
ja matemaatilisele modelleerimisele. Veelgi enam, uuring näitas, et MTO 
poolt soovitatud süstemaatiline TB-ile suunatud läbivaatus toimib tõhusalt 
üksnes siis, kui diagnostikas kasutatakse kiirteste. Uuring I demonstreeris 
ka, et paremad ravitulemused on patsientidel, keda raviti esimese rea TB-
ravimitega peale Xpert MTB/RIF-i ja vedelkultuuri kasutuselevõttu süste-
maatilisel TB-ile suunatud skriinimisel vanglates. 
II. Diagnostilistes algoritmides võib testimiseks Xpert MTB/RIF ja MGIT-
kultuuridel kasutada järjestikuseid rögaproove, kuna lahknevate RIF-tund-
likkuse tulemuste määr ei sõltu sellest, kas kasutatakse üht ja sama proovi 
või erinevaid järjestikuseid proove. Kõige sagedamini täheldatud lahkne-
vate tulemuste muster on selline, kus RIF-resistentsus Xpert MTB/ RIF-l 
kombineerus RIF-tundlikkusega MGIT-kultuuris ning kus RIF-resistentsus 
oli peamiselt tingitud L511P mutatsioonist. RIF-resistentsuse kliiniline 
tähendus on aga sellistel juhtudel tõenäoliselt vähene, nagu näitasid suhte-
liselt soodsad ravitulemused. Siiski peaksid arstid olema praktikas teadli-
kud teatud lahknevustest RIF-resistentsuse molekulaarse ja fenotüübi-
põhise määramise tulemuste vahel ning olema teise rea TB ravimitega ravi-
mise korral valmis korrigeerima raviskeemi peale lõplike ravimtundlikkuse 
andmete saabumist.  
III. Suurema arvu efektiivsete bakteritsiidsete ravimite kasutamine pärast RR-
TB ravikuuri kuuendat kuud on peamiseks efektiivse raviga seotud tegu-
riks. Pikem raviperiood suurendas oluliselt ravi efektiivsust teise rea TB-
ravimitega ravitud patsientide hulgas ilma uute, MTO poolt hiljuti heaks-
kiidetud TB-ravimite lisamiseta. Patsiendid, kes vabastati kinnipidamis-
asutusest enne täieliku ravikuuri lõppu, vajavad täiendavat tuge, et suuren-
dada nende võimalusi ravi efektiivselt lõpule viia. Olukord, kus kopsudes 
ei ole radioloogilise muutusi ja kehamassiindeks (BMI) on vähemalt  
18,5 kg/m2, suurendab samuti oluliselt efektiivse ravi tõenäosust. Üks 
olulisi eduka ravitulemuse saavutamise teid on ravikatkestajate arvu vähen-
damine RR-TB patsientide hulgas. 
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